Advertisement
Guest User

Untitled

a guest
Aug 24th, 2016
265
0
Never
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
text 110.58 KB | None | 0 0
  1. Cover
  2. Contents
  3. Editorial Team
  4. Principal Editors
  5. International Editors
  6. Specialist Advisory Editors
  7. Authors
  8. Beginnings
  9. Foreword to the First Edition
  10. Foreword to the Second Edition
  11. Preface
  12. Acknowledgements
  13. 1: Neurology Worldwide: The Epidemiology and Burden of Neurological Disease
  14. Epidemiology of neurological disease
  15. Frequency and distribution of neurological disease
  16. Causation
  17. Mortality
  18. Other measures and rates
  19. Burden of illness
  20. Definitions
  21. Cost of illness studies
  22. WHO burden of illness studies
  23. The personal burden of neurological disease – stigma
  24. Relative costs – developing countries
  25. Treatment gap
  26. References
  27. Further reading
  28. 2: Nervous System Structure and Function
  29. BASIC NEUROSCIENCE
  30. Introduction
  31. The functional unit: the neurone
  32. Amyloid and tau in Alzheimer’s disease
  33. Neurotransmission
  34. Electrical synapses
  35. Chemical synapses
  36. Types of CNS synapse
  37. Peripheral nervous system synapses
  38. Neuromuscular junction
  39. Neurotransmitters
  40. Transmitter release
  41. Transmitter‐gated ion channels and G‐protein‐coupled receptors
  42. Glia
  43. Astrocytes
  44. Oligodendrocytes (oligodendroglia)
  45. Microglia
  46. Ependyma
  47. Schwann cells
  48. Peripheral nerve fibre types
  49. Myelin and saltatory conduction
  50. Composition of the myelin sheath
  51. Glycoproteins
  52. Basic proteins
  53. Other proteins
  54. Myelination and axon–Schwann cell interactions
  55. Sensory nerve endings
  56. Muscle spindle motor supply, annulospiral and flower spray endings
  57. Golgi tendon organs
  58. THE WORKING BRAIN
  59. Introduction
  60. Mechanisms of movement
  61. Three central systems of motor control
  62. Corticospinal (pyramidal) system
  63. Afferents to the primary motor cortex
  64. Basal ganglia and ‘extrapyramidal’ movement disorders
  65. Basic circuits within the basal ganglia
  66. Other basal ganglia circuits
  67. Cerebellum
  68. Sensation and sensory pathways
  69. Conscious and non‐conscious sensation
  70. Somatic sensory pathways in the cord and brain
  71. Dorsal root ganglia – first order neurones
  72. Termination of dorsal root afferents
  73. Posterior column
  74. medial lemniscus pathway
  75. Spinothalamic pathway
  76. Other ascending sensory pathways
  77. The brainstem
  78. Brainstem functions
  79. Motor fibres
  80. Motor fibres to cranial nerve nuclei
  81. Sensory pathways within the brainstem
  82. Spinothalamic tracts
  83. Posterior column
  84. medial lemniscus
  85. Vth nerve central pathways
  86. Clinical correlates
  87. Cranial nerve nuclear columns
  88. Reticular formation
  89. Essential anatomy
  90. Respiratory control
  91. Sleep, wakefulness and mood
  92. Cardiovascular control
  93. Patterns of primitive movements
  94. Micturition control
  95. Gate control: sensory modulation
  96. Limbic system, hippocampus and related structures
  97. Afferent hippocampal connections
  98. Efferent hippocampal connections
  99. Declarative memory and long‐term potentiation
  100. Insula, cingulate cortex and parahippocampal gyrus
  101. Amygdala
  102. Nucleus accumbens
  103. Septal region
  104. Basal forebrain
  105. The thalamus
  106. Cortical connections
  107. Specific (relay) thalamic nuclei
  108. Association thalamic nuclei
  109. Non‐specific thalamic nuclei
  110. Hypothalamus and pituitary gland
  111. Arterial and capillary supply
  112. Neuroendocrine cells
  113. Anterior pituitary axis
  114. Posterior pituitary axis
  115. Circumventricular organs
  116. Sympathetic and parasympathetic hypothalamic activity
  117. Temperature regulation
  118. Water intake and thirst
  119. Appetite and satiety
  120. Mood, sexual arousal, wakefulness and memory
  121. Cranial nerves
  122. Olfactory nerve and its cortical connections
  123. Olfactory epithelium
  124. Olfactory bulb and tract
  125. Cortical connections
  126. Neurotransmission in the olfactory system
  127. Optic nerve and visual system
  128. Retinal structure
  129. Optic nerve, chiasm and optic tract
  130. Optic radiation
  131. Occipital cortex
  132. Visual association cortex and V1–V5 terminology
  133. Cortical eye fields
  134. Gaze centres in the brainstem
  135. The light reflex: pupil constriction
  136. III, IV and VI: third, fourth and sixth nerve nuclei and nerves
  137. Oculomotor nucleus and IIIrd nerve
  138. Trochlear nucleus and IVth nerve
  139. Abducens nucleus and VIth nerve
  140. The near response
  141. The far response
  142. Sympathetic pathway to the eye and face
  143. V: trigeminal nerve, sensory and motor nuclei
  144. Motor nucleus of V and supratrigeminal nuclei
  145. Sensory Vth nuclei
  146. Mesencephalic Vth nucleus
  147. Principal (pontine) Vth nucleus
  148. Spinal Vth nucleus
  149. Trigeminothalamic tract, lemniscus, cortical projection and reticular formation
  150. VII: facial nerve
  151. Nervus intermedius, greater petrosal nerve and chorda tympani
  152. VIII: vestibulocochlear nerve
  153. Vestibular system
  154. Auditory system
  155. Cochlear nerve and central connections
  156. IX, X, XI and XII: glossopharyngeal, vagus, accessory and hypoglossal nerves
  157. XI: spinal accessory nerve
  158. Cranial accessory XI, glossopharyngeal IX and vagus X – and their nuclei
  159. Glossopharyngeal nerve IX
  160. Vagus nerve X
  161. XII: hypoglossal nerve
  162. Autonomic nervous system
  163. Sympathetic system
  164. Parasympathetic system
  165. Cranial parasympathetic III, VII, IX and X fibres and subsequent ganglia
  166. Sacral parasympathetic fibres and ganglia
  167. Neurotransmission within the autonomic system
  168. Neurotransmission at sympathetic and parasympathetic ganglia
  169. Neuro‐effector junction transmission at target tissues
  170. Junctional receptors at target tissues
  171. Other autonomic neurotransmitter systems
  172. Acknowledgements
  173. Further reading
  174. 3: Mechanisms of Neurological Disease: Genetics, Autoimmunity and Ion Channels
  175. Genetics
  176. Modes of inheritance
  177. Autosomal dominant inheritance
  178. Autosomal recessive inheritance
  179. Sex‐linked inheritance
  180. Mitochondrial disorders
  181. Expanded repeat disorders
  182. How heritable are neurological conditions? Lessons from twins
  183. Mutation versus polymorphism
  184. The discovery process
  185. Practical considerations
  186. Ethical considerations: predictive versus diagnostic
  187. Incidental findings in diagnostic exome and genome sequencing
  188. Autoimmunity
  189. Fundamentals
  190. Components of the immune system
  191. Innate immune system
  192. Adaptive immune system
  193. Protection of neural tissues – the blood–brain and blood–nerve barriers
  194. Intrathecal antibody synthesis and the blood–brain barrier
  195. Analysis of CSF solutes
  196. Immune diseases of the nervous system
  197. Antibody‐mediated neurological diseases
  198. T‐cell mediated neurological disease
  199. Cytokine‐driven processes
  200. Interfering with the immune system as a treatment for disease
  201. Inherited mutations of ion channels
  202. Channelopathies
  203. Migraine
  204. Epilepsy
  205. Movement disorders and ataxia
  206. Disorders of peripheral nerve and autonomic function
  207. Muscle disease
  208. Psychiatric and cognitive disorders
  209. Disease causation in channelopathies
  210. Potassium channels
  211. Transient receptor potential channels
  212. Sodium channels
  213. Calcium channels
  214. Chloride channels
  215. Ligand‐gated ion channels
  216. Acquired versus inherited channelopathies
  217. References
  218. Further reading
  219. Genetics
  220. Immunology
  221. Channelopathies
  222. 4: The Language of Neurology: Symptoms, Signs and Basic Investigations
  223. Elements of diagnosis
  224. History
  225. Nature of symptoms
  226. Neurological examination
  227. Preliminary assessment
  228. Brief neurological examination
  229. Detailed neurological examination
  230. Cognition and mental state
  231. Skull, scalp and spine
  232. Cranial nerves
  233. I: olfaction
  234. II: vision, pupils and fundi
  235. III, IV and VI: eye movements
  236. V: trigeminal nerve – sensory and motor
  237. VII: facial nerve
  238. VIII: auditory nerve
  239. VIII: vestibular nerve
  240. IX and X: glossopharyngeal and vagus nerves
  241. XI: accessory nerve
  242. XII: hypoglossal nerve
  243. Gait and disorders of movement
  244. Motor system
  245. Posture of outstretched upper limbs
  246. Tone
  247. Power, muscle bulk and consistency
  248. Coordination – cerebellar signs
  249. Tendon reflexes
  250. Lower and upper motor neurone lesions
  251. Sensory system
  252. Formulation and diagnosis
  253. Difficulties with the history and examination
  254. Diagnostic tests in clinical neurology
  255. Imaging
  256. Conventional radiography (plain X‐rays)
  257. Computerised tomography
  258. Magnetic resonance imaging
  259. Clinical neurophysiology
  260. Electroencephalography
  261. Magneto‐encephalography and transcranial magnetic brain stimulation
  262. Clinical neurophysiological studies of nerve and muscle
  263. Electromyography
  264. Peripheral nerve conduction studies
  265. Neuromuscular transmission studies
  266. Cerebral‐evoked potentials
  267. Specialised blood and urine tests
  268. Cerebrospinal fluid examination
  269. Indications for LP and CSF examination
  270. LP technique
  271. Biopsy of brain, nerve and muscle
  272. Neuropsychological testing
  273. Intellectual function overall
  274. Formulation and conclusions
  275. Terminology, or vocabulary of clinical neurology
  276. Focal cortical disorders
  277. Language (and speech) disorders
  278. Temporal lobe lesions
  279. Frontal lobe lesions
  280. Occipital lobe lesions
  281. Parietal lobe lesions
  282. Motor abnormalities: brain and spinal cord
  283. Hemiparesis
  284. Cerebellar syndromes
  285. Disorders of movement
  286. Paraparesis
  287. Brainstem syndromes
  288. Anterior horn cell disease
  289. Sensory abnormalities: patterns at different levels
  290. Peripheral nerve lesions
  291. Sensory root and root entry zone lesions
  292. Spinal cord lesions
  293. Sensory changes in brainstem lesions
  294. Sensory changes following thalamic lesions
  295. Sensory changes in parietal lobe lesions
  296. Mononeuropathy, polyneuropathy, root lesions
  297. Mononeuropathy
  298. Multiple mononeuropathy
  299. Polyneuropathy
  300. Neurogenic muscle wasting
  301. Root lesions
  302. Cauda equina syndrome
  303. Myopathy
  304. Subacute paralytic conditions
  305. Unexplained symptoms, abnormal illness behaviour and somatoform disorder
  306. References
  307. Further reading
  308. General neurology, examination, classic works
  309. Nerve conduction and electromyography
  310. Electroencephalography
  311. CSF examination
  312. Neuropsychiatry
  313. Neuropsychology screening tests
  314. Imaging
  315. 5: Stroke and Cerebrovascular Diseases
  316. Epidemiology
  317. Clinical approach to stroke
  318. Ischaemic stroke
  319. Important vascular anatomy
  320. Heart and great vessels
  321. Extracranial and intracranial arteries
  322. Venous anatomy
  323. Pathophysiology of ischaemic stroke
  324. Thrombosis, embolism and hypoperfusion
  325. Microscopic and metabolic changes
  326. Ischaemic penumbra
  327. Pressure changes
  328. Risk factors and causes of ischaemic stroke
  329. Age, hypertension, smoking, lipids and drug misuse
  330. Cardiac disease
  331. Stroke and the blood
  332. Antiphospholipid antibodies and syndrome
  333. Clinical syndromes of cerebral ischaemia
  334. Transient ischaemic attacks
  335. Alternative diagnoses
  336. Lacunar stroke
  337. Rarer causes of lacunar syndromes
  338. Large vessel occlusion
  339. Internal carotid artery disease
  340. Middle cerebral artery occlusion
  341. Anterior cerebral artery occlusion
  342. Anterior choroidal artery occlusion
  343. Posterior cerebral artery
  344. Vertebral artery
  345. Basilar artery
  346. Border‐zone syndromes and ischaemic encephalopathy
  347. Vascular dementia
  348. Intracranial haemorrhage
  349. Risk factors
  350. Clinical syndromes of intracranial haemorrhage
  351. Deep haemorrhage
  352. Lobar haemorrhage
  353. Infratentorial haemorrhage
  354. Intraventricular haemorrhage
  355. Specific issues in intracerebral haemorrhage
  356. Prognosis of intracranial haemorrhage
  357. Subarachnoid haemorrhage
  358. Risk factors
  359. Clinical features
  360. Investigation
  361. Initial management
  362. Aneurysm treatment
  363. Management of complications
  364. Outcome
  365. Arteriovenous malformations
  366. Presentation
  367. Natural history
  368. Management
  369. Cavernous malformations
  370. Dural fistulae
  371. Investigation of stroke and TIAs
  372. Basic investigations for all: simple tests
  373. Imaging
  374. Guided investigations following basic profile
  375. Cardiac investigations
  376. Special investigations
  377. Management of acute stroke
  378. Organised care in a stroke unit
  379. Specific treatments for acute ischaemic stroke
  380. Thrombolysis
  381. Mechanical recanalisation
  382. Antiplatelet therapy in acute stroke
  383. Anticoagulation in thrombo‐embolic stroke
  384. Neuroprotection
  385. Maintenance of homeostasis
  386. Treatment of cerebral oedema
  387. Management of progressive stroke
  388. Common medical complications of stroke
  389. Secondary prevention
  390. Secondary prevention after TIA and stroke
  391. Lifestyle modification
  392. Lowering blood pressure
  393. Diabetes mellitus
  394. Lowering cholesterol
  395. Anticoagulation
  396. Antiplatelet therapy
  397. Management of carotid stenosis
  398. Symptomatic carotid stenosis
  399. Asymptomatic carotid stenosis
  400. Carotid stenting
  401. Vertebral stenosis
  402. Intracranial artery stenosis
  403. Non‐atherosclerotic vascular disease and other rarer causes of stroke
  404. Carotid and vertebral artery dissection
  405. Vasculitis
  406. Infective vasculitis
  407. Systemic vasculitides
  408. Collagen vascular disease
  409. Other vasculitis
  410. Isolated angiitis of the central nervous system
  411. Thrombotic thrombocytopenic purpura
  412. Behçet’s disease
  413. Susac’s syndrome
  414. Sneddon’s syndrome
  415. Mitochondrial disease
  416. Fabry disease
  417. CADASIL and CARASIL
  418. Hypertensive encephalopathy
  419. Migraine and stroke
  420. Moyamoya angiopathy
  421. Cerebral venous thrombosis
  422. Reversible cerebral vasoconstriction syndrome
  423. Vascular disease of the spinal cord
  424. Stroke: overall conclusions
  425. References
  426. Further reading
  427. Anticoagulation
  428. Arteriovenous malformations
  429. Atrial fibrillation
  430. CADASIL
  431. Carotid stenosis
  432. Causes of stroke
  433. Cavernous angiomas
  434. Cerebral amyloid angiopathy
  435. Dissection
  436. Fabry’s disease
  437. Endovascular treatment of hyperacute stroke
  438. Fibromuscular dysplasia
  439. Haematological disorders
  440. Hypertension
  441. Incidence, prevalence and prognosis
  442. Inflammatory vascular disorders
  443. Mitochondrial disease and MELAS
  444. Moyamoya syndrome
  445. Patent foramen ovale
  446. Radiology
  447. Secondary prevention
  448. Stroke definition
  449. Stroke units and organisation
  450. Subarachnoid haemorrhage
  451. Surgical treatment
  452. Thrombolytic therapy
  453. Transient ischaemic attack
  454. Venous thrombosis
  455. 6: Movement Disorders
  456. Parkinsonian (akinetic‐rigid) syndromes
  457. Cardinal motor features of parkinsonism
  458. Parkinson’s disease
  459. Premotor features of PD
  460. Typical’ motor presentation of PD
  461. Non‐motor features of PD
  462. Ancillary investigations
  463. Treatment of PD
  464. Levodopa
  465. Monoamine oxidase B inhibitors
  466. Catechol‐
  467. methyl transferase inhibitors
  468. Dopamine agonists
  469. Anticholinergics
  470. Amantadine
  471. Surgery for PD
  472. Dementia in association with Lewy body pathology
  473. Multiple system atrophy
  474. Progressive supranuclear palsy
  475. Corticobasal degeneration
  476. Ancillary investigations to distinguish between PD, MSA, PSP and CBD and other conditions
  477. Vascular parkinsonism
  478. Ethnic or region‐specific parkinsonism
  479. Other causes of parkinsonism
  480. Tremor
  481. Benign essential tremor
  482. Dystonic tremor
  483. Neuropathic tremor
  484. Fragile X tremor ataxia syndrome
  485. Cerebellar (pathway) tremor
  486. Intention tremor
  487. Holmes tremor
  488. Palatal tremor
  489. Orthostatic tremor
  490. Drug and toxin‐induced tremor
  491. Psychogenic tremor
  492. Dystonia
  493. Epidemiology
  494. Classifying dystonia
  495. Primary dystonia
  496. Dystonia‐plus syndromes
  497. Dopa‐responsive dystonia
  498. Myoclonus dystonia
  499. Symptomatic dystonia
  500. Heredodegenerative dystonias
  501. Wilson’s disease
  502. Clinical presentations
  503. Diagnosis
  504. Treatment
  505. Paroxysmal dyskinesias
  506. Investigation of dystonia
  507. Treatment of dystonia
  508. Surgery for dystonia
  509. Chorea
  510. Assessment of chorea
  511. Huntington’s disease
  512. Clinical features
  513. Juvenile Huntington’s disease
  514. Differential diagnosis of Huntington’s disease
  515. Neuro‐acanthocytosis
  516. Post‐streptococcal autoimmune disorders
  517. Benign hereditary chorea
  518. Drug‐induced chorea
  519. Drug management of chorea
  520. Tics
  521. Gilles de la Tourette syndrome
  522. Epidemiology, history and prevalence
  523. Psychopathology and associated co‐morbidity
  524. Assessment
  525. Current aetiological theories
  526. Multiple phenotypes of GTS
  527. Other forms of tic disorder
  528. Other diseases that can cause tics
  529. Investigation of tics
  530. Management of GTS and tics
  531. Myoclonus
  532. Physiological myoclonus
  533. Essential myoclonus
  534. Epileptic myoclonus
  535. Familial cortical tremor (also called benign autosomal dominant familial myoclonic epilepsy)
  536. Epilepsia partialis continua
  537. Secondary myoclonus
  538. Non‐progressive myoclonic encephalopathies
  539. Post‐anoxic action myoclonus (Lance–Adams syndrome)
  540. Opsoclonus myoclonus
  541. Myoclonus in neurodegenerative disorders
  542. Subcortical myoclonus
  543. Startle syndromes
  544. Palatal myoclonus
  545. Spinal myoclonus
  546. Peripheral myoclonus
  547. Psychogenic myoclonus
  548. Drug‐induced myoclonus
  549. Treatment of myoclonus
  550. Other movement disorders
  551. Psychogenic (functional) movement disorders
  552. Movement disorders associated with dopamine receptor blockade or dopamine depletion
  553. Restless legs syndrome
  554. Painful legs and moving toes
  555. Stiff person syndrome, stiff limb syndrome and encephalomyelitis with rigidity
  556. Neurophysiological assessment of movement disorders
  557. Neurophysiological assessment of tremor
  558. Neurophysiological assessment of dystonia
  559. Neurophysiological assessment of myoclonus
  560. Cortical myoclonus
  561. Reticular, or brainstem, myoclonus
  562. Spinal myoclonus
  563. Further reading
  564. Parkinson’s disease and related disorders
  565. Chorea
  566. Wilson’s disease
  567. Dystonias
  568. Tics
  569. Tremor
  570. Myoclonus
  571. Psychogenic movement disorders
  572. Other movement disorders
  573. 7: Epilepsy and Related Disorders
  574. Definitions
  575. Epidemiology
  576. ILAE classification of seizure type
  577. Partial (focal) seizures
  578. Simple partial seizures
  579. Complex partial seizures
  580. Generalised seizures
  581. Typical absence seizure (petit mal seizure)
  582. Atypical absence seizure
  583. Myoclonic seizure
  584. Clonic seizure
  585. Tonic seizure
  586. Tonic–clonic seizure (grand mal seizure)
  587. Atonic seizure
  588. ILAE classification of the epilepsies and epilepsy syndromes
  589. Idiopathic generalised epilepsy
  590. Childhood absence epilepsy
  591. Juvenile myoclonic epilepsy
  592. Epilepsy with grand mal seizures on awakening
  593. Benign partial epilepsy syndromes
  594. Benign partial epilepsy with centrotemporal spikes
  595. Early onset benign occipital epilepsy (
  596. Panayiotopoulos syndrome)
  597. West syndrome
  598. Lennox–Gastaut syndrome
  599. Febrile seizures
  600. Causes of epilepsy
  601. Idiopathic epilepsy
  602. Pure epilepsies resulting from single gene disorder
  603. Pure epilepsies with complex inheritance
  604. Symptomatic epilepsy
  605. Inborn errors of metabolism
  606. Progressive myoclonic epilepsy
  607. Epilepsies in neurocutaneous syndromes
  608. Cortical dysplasia
  609. Hippocampal sclerosis
  610. Cerebral palsy, perinatal and prenatal injury
  611. Post‐vaccination encephalopathy
  612. Cerebral tumour
  613. Cerebrovascular disease
  614. Arteriovenous malformation
  615. Cavernous haemangioma (cavernoma)
  616. Other vascular lesions
  617. Dementia and degenerative disorders
  618. Post‐traumatic epilepsy
  619. Epilepsy after neurosurgery
  620. Bacterial or viral meningitis and encephalitis
  621. Parasitic diseases
  622. Inflammatory and immunological disorders
  623. Differential diagnosis of epilepsy
  624. Loss of awareness and collapse
  625. Epilepsy
  626. Syncope
  627. Cardiac syncope
  628. Dissociative seizures
  629. Panic attacks
  630. Hypoglycaemia
  631. Other neurological disorders
  632. Generalised convulsive movements
  633. Epilepsy
  634. Syncope with myoclonic jerking movements
  635. Primary cardiac or respiratory abnormalities presenting with secondary anoxic seizures
  636. Involuntary movement disorders and other neurological conditions
  637. Hyperekplexia
  638. Dissociative seizure
  639. Focal convulsive movements
  640. Focal motor seizures
  641. Tics
  642. Transient cerebral ischaemia
  643. Tonic spasms of multiple sclerosis
  644. Paroxysmal movement disorders
  645. Transient facial muscle and eye movements
  646. Partial seizures
  647. Movement disorders
  648. Other neurological disorders
  649. Drop attacks
  650. Epilepsy
  651. Cardiovascular causes
  652. Movement disorders
  653. Brainstem, spinal or lower limb abnormalities
  654. Cataplexy
  655. Metabolic disorders
  656. Idiopathic drop attacks
  657. Vertebrobasilar ischaemia
  658. Transient focal sensory symptoms
  659. Transient vestibular symptoms
  660. Transient visual symptoms
  661. Transient psychic experiences
  662. Epilepsy
  663. Migraine
  664. Panic attacks
  665. Drug‐induced flashbacks
  666. Hallucinations or illusions caused by loss of a primary sense
  667. Psychotic hallucinations and delusions
  668. Dissociative seizures
  669. Aggressive outbursts
  670. Episodic phenomena in sleep
  671. Normal physiological movements
  672. Frontal lobe epilepsy
  673. Other epilepsies
  674. Pathological fragmentary myoclonus
  675. Restless leg syndrome
  676. Non‐REM parasomnia
  677. REM parasomnia
  678. Sleep apnoea
  679. Other movements in sleep
  680. Prolonged confusional or fugue states
  681. Acute encephalopathy
  682. Non‐convulsive status epilepticus
  683. Intermittent psychosis
  684. Transient global amnesia
  685. Hysterical fugue
  686. Investigation of epilepsy
  687. Routine tests to carry out in all cases
  688. Biochemical, haematological and immunological tests
  689. Electroencephalography
  690. EEG in the diagnosis of epilepsy
  691. Epileptiform phenomena
  692. EEG in the classification of epileptic seizures and syndromes
  693. EEG and prediction of seizure recurrence
  694. EEG and withdrawal of antiepileptic medication
  695. EEG and antiepileptic drugs
  696. Long‐term EEG monitoring
  697. Neurophysiology for assessing patients for epilepsy surgery
  698. EEG and tonic–clonic status epilepticus
  699. Non‐convulsive status epilepticus
  700. EEG in the intensive care setting
  701. EEG and cognitive deterioration
  702. Imaging in epilepsy
  703. X‐ray computed tomography
  704. Magnetic resonance imaging
  705. Functional magnetic resonance imaging
  706. Tractography
  707. Single‐photon emission computed tomography
  708. Positron emission tomography
  709. Medical treatment
  710. Principles of treatment of newly diagnosed patients
  711. Diagnosis
  712. Risk of recurrence of seizure
  713. Type, timing and frequency of seizure
  714. A protocol for initial treatment
  715. Treatment protocol for patients with chronic epilepsy
  716. Assessment
  717. Treatment plan
  718. Limits of therapy
  719. Choice of drugs and details of antiepileptic drugs
  720. Monotherapy versus combination therapy
  721. Role of antiepileptic drug level measurements
  722. Patient information
  723. Treatment of patients with epilepsy in remission
  724. Discontinuation of drug therapy
  725. How to withdraw therapy – the importance of slow reduction
  726. Management of epilepsy in learning disability
  727. Definition
  728. Prevalence of epilepsy in people with learning disability
  729. Assessment
  730. Diagnostic difficulties
  731. Treatment
  732. Management in the elderly
  733. Causes of epilepsy
  734. Diagnosis and investigations
  735. Medical treatment
  736. Antiepileptic drug treatment
  737. Acetazolamide
  738. Benzodiazepines
  739. Carbamazepine
  740. Eslicarbazepine acetate
  741. Ethosuximide
  742. Felbamate
  743. Gabapentin
  744. Lacosamide
  745. Lamotrigine
  746. Levetiracetam
  747. Oxcarbazepine
  748. Perampanel
  749. Phenobarbital
  750. Phenytoin
  751. Piracetam
  752. Pregabalin
  753. Primidone
  754. Retigabine
  755. Rufinamide
  756. Stiripentol
  757. Tiagabine
  758. Topiramate
  759. Valproate
  760. Vigabatrin
  761. Zonisamide
  762. Emergency drug treatment
  763. Prolonged convulsions or serial seizures
  764. Status epilepticus
  765. Treatment of non‐convulsive status epilepticus
  766. Treatment of convulsive status epilepticus
  767. Stage of early status epilepticus
  768. Stage of established status epilepticus
  769. Stage of refractory status epilepticus
  770. Stage of super‐refractory status epilepticus
  771. Epilepsy surgery
  772. Who is suitable for presurgical assessment?
  773. Presurgical assessment
  774. Clinical history
  775. Psychiatric history
  776. Neuroimaging
  777. Electroencephalography and other neurophysiological investigations
  778. Neuropsychology
  779. Counselling
  780. Surgery
  781. Curative resective surgery
  782. Palliative procedures
  783. Follow‐up and prognosis
  784. Driving regulations in the UK
  785. Group 1 licensing
  786. Group 2 licensing
  787. For both types of licence
  788. Role of the doctor vis‐à‐vis the driving regulations
  789. Other types of vehicle
  790. Acknowledgement
  791. References
  792. Further reading
  793. Useful websites with epilepsy information for patients
  794. Books
  795. Journal articles
  796. 8: Dementia and Cognitive Impairment
  797. Epidemiology: Delirium, dementia and cognitive impairment
  798. Cognitive functions and their clinical syndromes
  799. Attention
  800. Memory
  801. Paramnesias
  802. Transient global amnesia
  803. Perception
  804. Hallucinations
  805. Knowledge
  806. Voluntary action
  807. Speech and language
  808. Literacy and numeracy
  809. Executive function
  810. Emotion
  811. Investigation of the patient with cognitive impairment
  812. Basic principles
  813. Initial investigation
  814. Neuropsychometry
  815. Brain imaging
  816. Electroencephalography
  817. Cerebrospinal fluid examination
  818. Additional investigations
  819. The dementias
  820. Alzheimer’s disease
  821. Clinical features and assessment
  822. Investigations
  823. Management
  824. Frontotemporal dementia
  825. Behavioural variant frontotemporal dementia
  826. Semantic dementia
  827. Progressive non‐fluent aphasia
  828. Investigations
  829. Genetic pathological correlations
  830. Prognosis
  831. Management
  832. Dementia with Lewy bodies and Parkinson’s disease dementia
  833. Dementia with other movement disorders
  834. Prion disease
  835. Introduction and disease biology
  836. Aetiological categories and classification of human prion disease
  837. Sporadic prion disease
  838. Acquired prion diseases
  839. Inherited prion diseases
  840. Prevention and treatment
  841. Vascular dementia and vascular cognitive impairment
  842. Dementia in young adults
  843. Potentially reversible causes of dementia
  844. Neoplasms and other space‐occupying lesions
  845. Epilepsy and dementia
  846. Limbic encephalitis
  847. Infective, metabolic, toxic and other causes of dementia
  848. Controversial entities
  849. Management of dementia
  850. Risk factor management
  851. Co‐morbidity
  852. Behavioural management
  853. Safety
  854. Caring for the carer
  855. Planning for the future and end of life issues
  856. References
  857. Further reading
  858. Epidemiology
  859. Cognitive function and clinical syndromes
  860. Investigations
  861. Alzheimer’s disease
  862. Frontotemporal lobar degeneration
  863. Vascular cognitive impairment
  864. Parkinson’s disease dementia and dementia with Lewy bodies
  865. Dementia in young adults: general
  866. Others
  867. Management
  868. Treatment of Alzheimer’s disease
  869. 9: Infection in the Nervous System
  870. Bacterial meningitis
  871. Epidemiology
  872. Pathogenesis
  873. Clinical presentation
  874. Investigation
  875. Management
  876. Specific causes of bacterial meningitis
  877. meningococcal meningitis)
  878. pneumococcal meningitis)
  879. type b
  880. Group B streptococcus
  881. Gram‐negative meningitis
  882. Gram‐positive meningitis (non‐pneumococcal, non‐group B)
  883. Nosocomial meningitis
  884. Focal CNS infection
  885. Cerebral abscess
  886. Clinical features
  887. Investigations
  888. Treatment
  889. Surgical intervention
  890. Prognosis
  891. Subdural empyema
  892. Pathophysiology
  893. Causative agents
  894. Intracranial epidural abscess
  895. Spinal epidural abscess
  896. Spinal subdural abscess
  897. Spinal cord intramedullary abscess
  898. Infective endocarditis
  899. Granulomatous infections of the nervous system
  900. CNS tuberculosis
  901. Tuberculous meningitis
  902. Parenchymal CNS tuberculosis
  903. Tuberculous abscess
  904. Spinal tuberculosis (tuberculous spondylitis)
  905. Leprosy (Hansen’s disease)
  906. Clinical features
  907. Peripheral nerve involvement
  908. Borderline leprosy
  909. Primary neuritic leprosy
  910. Diagnosis
  911. Management
  912. Brucellosis (undulant fever)
  913. Spirochete CNS infections
  914. Syphilis
  915. Late neurosyphilis
  916. Intracerebral gumma
  917. Diagnosis
  918. Treatment
  919. Zoonoses
  920. Lyme neuroborreliosis
  921. Clinical features of early neuroborreliosis
  922. Early disseminated infection
  923. Cranial neuropathy
  924. Acute radiculoneuropathy
  925. Other syndromes
  926. Clinical features of late neuroborreliosis
  927. Post Lyme syndrome
  928. Diagnosis
  929. Treatment
  930. Leptospirosis
  931. Anthrax
  932. Psittacosis
  933. Cat scratch disease
  934. Infections of the nervous system associated with toxin production
  935. Diphtheria
  936. Management
  937. Botulism
  938. Forms of botulism
  939. Clinical presentation
  940. Diagnosis
  941. Neurophysiology
  942. Management
  943. Tetanus
  944. Epidemiology
  945. Clinical features
  946. Diagnosis
  947. Differential diagnosis
  948. Treatment
  949. Miscellaneous infections of the nervous system
  950. Mycoplasma
  951. Whipple’s disease
  952. Melioidosis
  953. Tick‐borne disease
  954. Ehrlichiosis
  955. Tularaemia
  956. Rickettsial disease
  957. Viral infections of the nervous system
  958. Viral meningitis
  959. Aetiology
  960. Clinical features
  961. Diagnosis
  962. Viral isolation
  963. Management and prognosis
  964. Chronic and recurrent meningitis
  965. Mollaret’s meningitis
  966. Encephalitis
  967. Pathophysiology
  968. Incidence
  969. Clinical features
  970. Diagnosis
  971. Herpes simplex encephalitis
  972. Other causes of encephalitis
  973. Arboviruses (arthropod‐borne viruses)
  974. Viral haemorrhagic fevers
  975. Polio and the post‐polio syndrome
  976. Differential diagnosis
  977. Prevention
  978. Post‐polio syndrome
  979. Subacute sclerosing panencephalitis
  980. Rabies
  981. Clinical features
  982. Diagnosis
  983. Management
  984. HTLV‐1
  985. HTLV‐1 associated myelopathy (tropical spastic paraparesis)
  986. Other neurological manifestions of HTLV‐1 infection
  987. HTLV‐2
  988. Fungal infections
  989. Risk factors
  990. True yeasts
  991. Histoplasmosis
  992. Coccidiomycosis
  993. Pseudohyphae
  994. species
  995. True hyphae (moulds)
  996. Mucormycosis
  997. Parasitic disease of the nervous system
  998. Neurocysticercosis
  999. Clinical features
  1000. Diagnosis
  1001. Management
  1002. Trematodes
  1003. Schistosomiasis (bilharzia)
  1004. Protozoa
  1005. American trypanosomiasis (Chagas disease)
  1006. African trypanosomiasis (sleeping sickness)
  1007. Malaria
  1008. Diagnosis
  1009. Acute management
  1010. Prevention
  1011. Neurological disorders resulting from HIV
  1012. Basic principles of neuroAIDS
  1013. Opportunistic infections in HIV
  1014. Tuberculous meningitis and brain abscess
  1015. Cryptococcal meningitis
  1016. Cytomegalovirus infection
  1017. Herpes simplex virus
  1018. Varicella‐zoster virus
  1019. Progressive multifocal leukoencephalopathy
  1020. Primary CNS lymphoma
  1021. Neurological complications resulting directly from HIV
  1022. HIV‐associated neurocognitive disorders
  1023. HIV‐related vacuolar myelopathy
  1024. HIV‐related neuropathy
  1025. Diffuse inflammatory lymphocytosis syndrome
  1026. Toxic neuropathy for antiretroviral drugs
  1027. HIV‐associated myopathy
  1028. Motor neurone disease
  1029. Immune reconstitution inflammatory syndrome
  1030. Conclusions
  1031. Acknowledgement
  1032. References
  1033. Further reading
  1034. Bacterial meningitis
  1035. Tuberculosis
  1036. Syphilis and leprosy
  1037. Toxins
  1038. Zoonoses
  1039. Viral infections
  1040. Tropical diseases
  1041. HIV‐related
  1042. 10: Nerve and Muscle Disease
  1043. Peripheral nerve disorders
  1044. Macro‐anatomy of the peripheral nerve
  1045. Upper limbs
  1046. Lower limbs
  1047. Micro‐anatomy of the peripheral nerve
  1048. Peripheral nerve compartments
  1049. Immunology
  1050. Pathophysiology of the peripheral nerve
  1051. Diseases of the peripheral nerve
  1052. General approach to peripheral nerve disease
  1053. History
  1054. Examination
  1055. Scores
  1056. Neurophysiology
  1057. Nerve biopsy
  1058. Inherited neuropathies
  1059. Charcot–Marie–Tooth disease and related disorders
  1060. An approach to the diagnosis of CMT and related disorders
  1061. Charcot–Marie–Tooth disease
  1062. Hereditary sensory neuropathy
  1063. Distal hereditary motor neuropathy
  1064. Hereditary neuralgic amyotrophy
  1065. Importance of a genetic diagnosis in CMT and related disorders
  1066. Familial amyloid polyneuropathy
  1067. Transthyretin‐related familial amyloid polyneuropathy
  1068. Apolipoprotein A‐1 related FAP
  1069. Gelsolin‐related FAP
  1070. Beta‐2 microglobulin FAP
  1071. Acquired neuropathies
  1072. Inflammatory neuropathies
  1073. Acute neuromuscular weakness and the inflammatory neuropathies
  1074. Guillain–Barré syndrome and its variants
  1075. Chronic inflammatory neuropathies
  1076. Chronic inflammatory demyelinating polyradiculoneuropathy
  1077. CIDP variants
  1078. Paraproteinaemic neuropathies
  1079. Vasculitic neuropathies
  1080. Other acquired peripheral nerve disorders
  1081. Endocrine disorders
  1082. Toxic, nutritional and metabolic peripheral neuropathies
  1083. Metabolic neuropathies
  1084. Critical illness neuromyopathy
  1085. Small fibre neuropathies
  1086. Idiopathic axonal neuropathy
  1087. Focal and compressive neuropathies
  1088. Median nerve compression and carpal tunnel syndrome
  1089. Carpal tunnel syndrome
  1090. Ulnar nerve compression
  1091. Common peroneal neuropathies
  1092. Plexopathies
  1093. Acute brachial neuritis
  1094. Anterior horn cell diseases
  1095. Motor neurone disease
  1096. Amyotrophic lateral sclerosis
  1097. Progressive bulbar palsy
  1098. Flail arm/leg syndrome
  1099. Primary lateral sclerosis
  1100. Progressive muscular atrophy
  1101. Cognitive involvement
  1102. Other forms
  1103. Aetiology
  1104. Diagnosis of MND
  1105. Investigations
  1106. Incidence and prognosis
  1107. Management
  1108. Spinal muscular atrophy
  1109. Genetics and aetiology
  1110. Clinical features
  1111. Investigation
  1112. Management
  1113. Disorders of the neuromuscular junction
  1114. Myasthenia gravis
  1115. Antibody negative’ myasthenia gravis – Anti MuSK antibodies
  1116. Clinical features
  1117. Diagnostic tests
  1118. Management
  1119. Ocular myasthenia gravis
  1120. Pregnancy and myasthenia
  1121. Myasthenic crisis
  1122. Cholinergic crisis
  1123. Anaesthesia and peri‐operative care
  1124. Other causes of abnormal neuromuscular transmission
  1125. Lambert–Eaton myasthenic syndrome
  1126. Clinical features
  1127. Aetiology
  1128. Investigations
  1129. Treatment
  1130. Congenital myasthenia
  1131. Clinical features
  1132. Investigation
  1133. Management
  1134. Muscle diseases
  1135. Basic muscle biology
  1136. Clinical assessment of the patient with muscle disease
  1137. History
  1138. Examination
  1139. Investigation of muscle diseases
  1140. Creatine kinase
  1141. Neurophysiology
  1142. Muscle biopsy
  1143. Metabolic testing
  1144. Genetic testing
  1145. Genetic muscle diseases
  1146. Muscular dystrophies
  1147. Congenital myopathies
  1148. Skeletal muscle channelopathies (Chapter 3)
  1149. Metabolic muscle disease
  1150. Mitochondrial respiratory chain diseases
  1151. Glycogenoses and lipid storage disorders (Chapter 19)
  1152. Acquired muscle diseases
  1153. Inflammatory myopathies
  1154. Idiopathic inflammatory myopathies
  1155. Dermatomyositis
  1156. Polymyositis
  1157. Inclusion body myositis
  1158. Investigation of inflammatory myopathy
  1159. Extended investigation of inflammatory myopathies
  1160. Treatment of idiopathic inflammatory myopathies
  1161. Other rare inflammatory myopathies
  1162. Necrotising autoimmune myopathy
  1163. Drugs and myopathy
  1164. Rhabdomyolysis
  1165. References
  1166. Further reading
  1167. Hereditary neuropathy
  1168. Amyloidosis
  1169. Acquired neuropathies
  1170. Motor neurone disease and spinal muscular atrophy
  1171. Myasthenia gravis
  1172. Muscular dystrophy and congenital myopathies
  1173. Myotonic dystrophy
  1174. Muscle channelopathies
  1175. Mitochondrial disease
  1176. Metabolic muscle disease
  1177. Inflammatory myopathy
  1178. 11: Multiple Sclerosis and Demyelinating Diseases
  1179. Epidemiology
  1180. Migration studies
  1181. Health economics
  1182. Aetiology
  1183. Genetic susceptibility
  1184. Environmental factors
  1185. Transmissible agents
  1186. Vitamin D and sunlight exposure
  1187. Smoking
  1188. Pathophysiology
  1189. Pathology
  1190. Autoimmune pathogenesis
  1191. Clinical course
  1192. Types of multiple sclerosis
  1193. Relapsing remitting multiple sclerosis
  1194. Secondary progressive multiple sclerosis
  1195. Primary progressive multiple sclerosis
  1196. Progressive relapsing multiple sclerosis
  1197. Natural history and prognosis
  1198. Clinically isolated syndrome
  1199. Established multiple sclerosis
  1200. Benign multiple sclerosis
  1201. Aggressive multiple sclerosis
  1202. Early onset multiple sclerosis
  1203. Mortality
  1204. Factors affecting relapse activity
  1205. Infections
  1206. Pregnancy
  1207. Stress
  1208. Vaccines
  1209. Clinical features
  1210. Diagnosis
  1211. Diagnostic investigations
  1212. Magnetic resonance imaging
  1213. Cerebrospinal fluid
  1214. Evoked potentials
  1215. Autoantibodies
  1216. Diagnostic criteria
  1217. Schumacher criteria
  1218. Poser criteria
  1219. McDonald 2001 criteria
  1220. McDonald 2005 criteria
  1221. McDonald 2010 criteria
  1222. Diagnostic criteria for primary progressive multiple sclerosis
  1223. Radiologically isolated syndrome
  1224. Differential diagnosis
  1225. The diagnostic process
  1226. Management
  1227. Education and support
  1228. Management of acute relapses
  1229. Assessment
  1230. Treatment
  1231. Disease‐modifying therapy
  1232. Currently available therapies
  1233. Interferon β and glatiramer acetate
  1234. Interferon β‐1b
  1235. Intramuscular interferon
  1236. Intramuscular interferon β‐1a
  1237. Subcutaneous interferon β‐1a
  1238. PEGylated interferon β
  1239. Glatiramer acetate
  1240. Natalizumab
  1241. Fingolimod
  1242. Teriflunomide
  1243. Alemtuzumab
  1244. Dimethyl fumarate
  1245. Initiation of treatment
  1246. Discontinuation of treatment
  1247. Emerging therapies
  1248. Other therapies
  1249. Future immunomodulatory therapies
  1250. Neuroprotection and remyelination
  1251. Disease‐modifying therapy in primary progressive multiple sclerosis
  1252. Symptomatic treatment
  1253. Fatigue
  1254. Spasticity
  1255. Weakness
  1256. Ataxia
  1257. Bladder and bowel dysfunction
  1258. Sexual dysfunction
  1259. Pain and paroxysmal symptoms
  1260. Cognitive and psychiatric dysfunction
  1261. Visual dysfunction
  1262. Vertigo
  1263. Bulbar and respiratory dysfunction
  1264. Temperature sensitivity
  1265. Neurological rehabilitation
  1266. Vocational rehabilitation
  1267. Palliative care
  1268. Complementary and alternative medicine
  1269. Neuromyelitis optica
  1270. Epidemiology
  1271. Pathophysiology
  1272. Clinical features
  1273. Investigations
  1274. Diagnostic criteria
  1275. Course and natural history
  1276. Management
  1277. Acute para‐infectious inflammatory encephalopathies
  1278. Acute disseminated encephalomyelitis
  1279. Clinical features
  1280. Pathophysiology
  1281. Differential diagnosis
  1282. Investigations
  1283. Clinical course and prognosis
  1284. Management
  1285. Acute haemorrhagic leukoencephalitis
  1286. Clinical features
  1287. Investigations
  1288. Prognosis
  1289. Management
  1290. References
  1291. Further reading
  1292. Epidemiology and aetiology
  1293. Pathophysiology
  1294. Clinical course
  1295. Diagnosis
  1296. Management
  1297. Disease‐modifying therapy
  1298. Symptomatic treatment and neurological rehabilitation
  1299. Neuromyelitis optica
  1300. Acute disseminated encephalomyelitis
  1301. 12: Headache
  1302. Evaluation of the headache patient
  1303. Headache history taking
  1304. Examination of the patient with headache
  1305. Red flags for secondary headaches
  1306. Investigation of the patient with headache
  1307. Secondary headaches
  1308. Medication overuse headache
  1309. Headache caused by vascular disorders
  1310. Subarachnoid haemorrhage
  1311. Carotid and vertebral artery dissection
  1312. Giant cell arteritis
  1313. Headache caused by disturbance of intracranial pressure
  1314. Intracranial hypertension
  1315. Low pressure headaches (intracranial hypotension)
  1316. Primary headaches
  1317. Anatomy and physiology of headache
  1318. Migraine
  1319. Epidemiology
  1320. Clinical features
  1321. Assessment and investigations
  1322. Management
  1323. Tension‐type headache
  1324. Epidemiology
  1325. Clinical features
  1326. Investigations
  1327. Management
  1328. Trigeminal autonomic cephalalgias
  1329. Cluster headache
  1330. Epidemiology
  1331. Clinical features
  1332. Investigations
  1333. Management
  1334. Paroxysmal hemicrania
  1335. Short‐lasting unilateral neuralgiform headache attacks
  1336. Hemicrania continua
  1337. Other primary headaches
  1338. Primary cough headache
  1339. Primary exercise headache
  1340. Primary sex headache
  1341. Primary thunderclap headache
  1342. Primary stabbing headache
  1343. Nummular headache
  1344. Hypnic headache
  1345. New daily persistent headache
  1346. Chronic daily headache
  1347. References
  1348. Further reading
  1349. Background reading
  1350. Classification
  1351. Epidemiology and clinical features
  1352. Investigation
  1353. Specific and unusual headache syndromes
  1354. Treatments
  1355. 13: Cranial Nerve Disorders
  1356. I. Olfactory nerve
  1357. Functional anatomy
  1358. Symptoms
  1359. Examination
  1360. Causes of anosmia
  1361. Ageing
  1362. Upper respiratory infections, nasal and paranasal sinus disease
  1363. Trauma and surgery
  1364. Neurodegenerative disorders
  1365. Other causes of olfactory dysfunction
  1366. V. Trigeminal nerve
  1367. Examination
  1368. Peripheral Vth nerve lesions
  1369. Numb chin syndrome
  1370. Superior orbital fissure syndrome
  1371. Cavernous sinus syndrome
  1372. Nuclear Vth nerve lesions
  1373. Trigeminal neuralgia
  1374. Clinical features
  1375. Aetiology and pathogenesis
  1376. Treatment
  1377. Trigeminal sensory neuropathy
  1378. Herpes zoster ophthalmicus
  1379. Atypical facial pain
  1380. VII. Facial nerve
  1381. Functional anatomy
  1382. Examination
  1383. Supranuclear facial weakness
  1384. Nuclear VIIth lesions
  1385. Cerebellopontine angle syndrome
  1386. Facial canal syndrome
  1387. Lesions at and distal to the stylomastoid foramen
  1388. Bell’s palsy
  1389. Recurrent facial palsy
  1390. Bilateral facial weakness
  1391. Hemifacial spasm
  1392. Other involuntary facial movements
  1393. Lower four cranial nerves: IX, X, XI and XII
  1394. IX. Glossopharyngeal nerve
  1395. Functional anatomy
  1396. Examination
  1397. IXth nerve lesions, peripheral and central
  1398. Glossopharyngeal neuralgia
  1399. X. Vagus nerve
  1400. Functional anatomy
  1401. Clinical features
  1402. Causes and localisation of lesions
  1403. Investigation
  1404. XI. Accessory nerve
  1405. Functional anatomy
  1406. Examination and localisation of lesions
  1407. XIth nerve lesions
  1408. XII. Hypoglossal nerve
  1409. Functional anatomy
  1410. Localisation of lesions
  1411. Causes of XIIth nerve lesions
  1412. Investigation
  1413. Cranial nerve injury following carotid endarterectomy or carotid angioplasty with stenting
  1414. Jugular foramen syndrome
  1415. Bulbar and pseudobular palsy
  1416. Normal swallowing
  1417. Bulbar palsy
  1418. Pseudobulbar palsy
  1419. Dropped head syndrome
  1420. Multiple cranial neuropathies
  1421. Other causes of MCNs
  1422. Intracranial epidural abscess
  1423. Acknowledgement
  1424. References
  1425. Further reading
  1426. Trigeminal nerve (V)
  1427. Facial nerve (VII)
  1428. Bulbar and pseudobulbar palsy
  1429. Glossopharyngeal nerve (IX)
  1430. Accessory nerve (XI)
  1431. Hypoglossal nerve (XII)
  1432. Multiple cranial nerve palsies
  1433. 14: Neuro‐Ophthalmology
  1434. Unilateral visual failure
  1435. History
  1436. Mode of onset
  1437. Positive symptoms
  1438. Effect of light level
  1439. Direct questions
  1440. Examination
  1441. Visual acuity
  1442. Colour vision
  1443. Amsler’s test
  1444. Visual field testing
  1445. Fundus examination
  1446. Associated features
  1447. Bilateral visual failure
  1448. Special investigations in neuroophthalmology
  1449. Optical coherence tomography
  1450. Ultrasound
  1451. Clinical electrophysiology of the eye
  1452. Visual field testing
  1453. Fundus fluorescein angiography
  1454. Optic nerve disease
  1455. Optic neuropathy
  1456. Inflammatory optic neuropathies (optic neuritis)
  1457. Optic neuritis associated with multiple sclerosis
  1458. Optic neuritis associated with neuromyelitis optica (Devic’s syndrome)
  1459. Optic neuritis: chronic relapsing inflammatory optic neuropathy
  1460. Optic neuritis: infective disorders
  1461. Optic neuritis: sarcoid‐related optic neuropathy
  1462. Optic neuritis: neuroretinitis
  1463. Optic neuritis: optic perineuritis
  1464. Ischaemic ocular syndromes
  1465. Nosology of ischaemic syndromes
  1466. Central and branch retinal artery occlusion
  1467. Central and branch retinal vein occlusion
  1468. Non‐arteritic anterior ischaemic optic neuropathy
  1469. Anterior ischaemic optic neuropathy in giant cell arteritis and other vasculitides
  1470. Posterior ischaemic optic neuropathy
  1471. Chronic ocular ischaemic syndromes
  1472. Tumours affecting the optic nerve
  1473. Compressive or infiltrative optic neuropathy
  1474. Optic and optochiasmal glioma
  1475. Hereditary optic neuropathies
  1476. Autosomal dominant optic atrophy
  1477. Leber’s hereditary optic neuropathy
  1478. Toxic and nutritional optic neuropathies
  1479. Traumatic optic neuropathy
  1480. Radiation‐induced optic neuropathy
  1481. Swollen optic disc
  1482. Specific optic disc anomalies
  1483. Papilloedema
  1484. Idiopathic intracranial hypertension
  1485. Ocular involvement in other neurological disease
  1486. Uveomeningitic syndromes
  1487. Neoplasia
  1488. The phakomatoses in neuro‐ophthalmology
  1489. Neurofibromatosis types 1 and 2 (Chapters 16 and 26)
  1490. Von Hippel–Lindau disease (Chapter 26)
  1491. Tuberous sclerosis
  1492. Sturge–Weber syndrome (encephalo‐trigeminal angiomatosis)
  1493. Abnormalities of eye movements
  1494. Diplopia
  1495. Orbital disease
  1496. Thyroid ophthalmopathy
  1497. Orbital inflammatory syndromes
  1498. Cavernous sinus thrombosis
  1499. Carotico‐cavernous fistula
  1500. Myopathy
  1501. Mitochondrial disease
  1502. Oculopharyngeal dystrophy
  1503. Neuromuscular junction abnormalities
  1504. Cranial nerve palsies
  1505. Oculomotor nerve (IIIrd nerve palsy)
  1506. Abducens (V1th) nerve palsy
  1507. Trochlear (IVth) nerve palsy
  1508. Painful and combined ophthalmoplegia
  1509. Central disorders of eye movements
  1510. Saccadic eye movements
  1511. Horizontal gaze palsy
  1512. Vertical gaze palsy
  1513. Oculogyric crises
  1514. Internuclear ophthalmoplegia
  1515. One and a half syndrome
  1516. Wall‐eyed bilateral internuclear ophthalmoplegia
  1517. Internuclear ophthalmoplegia of abduction
  1518. Disconjugate vertical gaze palsy
  1519. Skew deviation and ocular tilt reaction
  1520. Nystagmus
  1521. Horizontal nystagmus
  1522. Nystagmus in normal subjects
  1523. Jerk nystagmus
  1524. Pendular nystagmus
  1525. Nystagmus in childhood
  1526. Pendular nystagmus from visual loss
  1527. Spasmus nutans
  1528. Monocular nystagmus
  1529. Vestibular jerk nystagmus
  1530. Gaze evoked or gaze paretic jerk nystagmus
  1531. Caloric nystagmus
  1532. Torsional nystagmus
  1533. Central vestibular horizontal nystagmus
  1534. Vertical and other forms of nystagmus
  1535. Downbeat nystagmus
  1536. Upbeat nystagmus
  1537. Nystagmus in oculopalatal tremor
  1538. See‐saw nystagmus
  1539. Oculomasticatory myorhythmia
  1540. Periodic alternating nystagmus
  1541. Convergence–retraction nystagmus in Parinaud’s syndrome
  1542. Voluntary nystagmus
  1543. Eye lid nystagmus
  1544. Medical treatment of nystagmus
  1545. Chiasmal and retrochiasmal visual pathways
  1546. Chiasmal disease
  1547. Homonymous hemianopia
  1548. Optic tract
  1549. Lateral geniculate nucleus
  1550. Optic radiation
  1551. Visual cortex
  1552. Bilateral homonymous hemianopia
  1553. Blindsight and stato‐kinetic dissociation
  1554. Visual association areas (extrastriate cortex areas V2–6)
  1555. Disorders of higher visual function
  1556. Visual hallucinations
  1557. Visual hallucinations associated with impaired vision (Charles Bonnet syndrome)
  1558. Peduncular hallucinosis
  1559. Polyopia
  1560. Palinopsia
  1561. Other disorders of visual perception
  1562. Pulfrich’s phenomenon
  1563. Hemifield slide
  1564. Tilt
  1565. Visual synaesthesia
  1566. Visual agnosia
  1567. Prosopagnosia
  1568. Disorders of colour vision
  1569. Cerebral metamorphopsia
  1570. Visual simultanagnosia
  1571. Cortical visual impairment
  1572. Neglect
  1573. Alexia
  1574. Abnormalities of the pupil
  1575. Disorders of the light reflex
  1576. Complete afferent pupillary defect
  1577. Relative afferent pupillary defect
  1578. Central (midbrain) lesions of the light reflex
  1579. Efferent parasympathetic defects of the light reflex
  1580. Holmes–Adie syndrome
  1581. Disorders of the sympathetic nervous supply to the pupil
  1582. Horner’s syndrome
  1583. References
  1584. Further reading
  1585. General texts
  1586. Unilateral and bilateral visual failure
  1587. Optic nerve disease
  1588. Ocular involvement in other neurological diseases
  1589. Diplopia
  1590. Central disorders of eye movements
  1591. Nystagmus
  1592. Chiasmal and retrochiasmal disorders
  1593. Disorders of higher visual function
  1594. Pupils
  1595. Dizziness and vertigo: introduction
  1596. Epidemiology
  1597. 15: Neuro‐Otology: Problems of Dizziness, Balance and Hearing
  1598. Basic concepts
  1599. Three‐dimensional spatial orientation
  1600. Vestibulo‐ocular reflexes
  1601. Encoding of head movements in space
  1602. Neuro‐otological assessment
  1603. Clinical examination
  1604. What to examine
  1605. When to examine what – the clinical presentation of balance disorders
  1606. What to examine
  1607. Brief neurological examination
  1608. Gait and posture
  1609. Nystagmus, eye movements, positional testing
  1610. Cover test
  1611. Spontaneous nystagmus
  1612. Gaze evoked nystagmus
  1613. Congenital nystagmus
  1614. Smooth pursuit eye movements
  1615. Saccadic eye movements
  1616. Optokinetic nystagmus
  1617. Vestibulo‐ocular reflexes
  1618. Doll’s head eye manoeuvre
  1619. Dynamic visual acuity
  1620. Head impulse test
  1621. Vestibulo‐ocular reflex suppression
  1622. Positional manoeuvres, Dix–Hallpike and roll manoeuvres
  1623. Orthostatic blood pressure
  1624. When to examine what – the clinical presentation of balance disorders
  1625. Acute vertigo
  1626. Recurrent vertigo
  1627. Chronic dizziness and/or unsteadiness
  1628. Commonly used vestibular investigations
  1629. Electronystagmograph
  1630. Clinical relevance of ENG
  1631. Rotary chair testing
  1632. Types of rotary chair stimuli
  1633. Clinical relevance of rotary chair testing
  1634. Video‐oculography
  1635. Caloric testing
  1636. Principles of caloric testing
  1637. Quantitative analysis
  1638. Closed‐circuit and air caloric testing
  1639. Clinical value of caloric testing
  1640. Posturography
  1641. Vestibular evoked myogenic potentials
  1642. Clinical disorders
  1643. Vestibular neuritis
  1644. Aetiology
  1645. Clinical assessment
  1646. Neuro‐otological investigations
  1647. Course
  1648. Differential diagnosis of vestibular neuritis
  1649. Benign paroxysmal positional vertigo
  1650. Incidence of BPPV
  1651. Posterior semicircular canal BPPV
  1652. Horizontal canal BPPV – geometric type
  1653. Apogeotropic horizontal canal BPPV
  1654. Anterior canal BPPV
  1655. Migraine‐related dizziness
  1656. Definitions
  1657. Basilar migraine
  1658. Vestibular migraine
  1659. Benign recurrent vertigo
  1660. Ménière’s disease
  1661. Bilateral vestibular failure
  1662. Vestibular paroxysmia
  1663. Motion sickness
  1664. Management of vestibular disorders
  1665. Drug treatment
  1666. Symptomatic treatment of acute vestibular symptoms
  1667. Specific treatment of vestibular disorders
  1668. Migraine
  1669. Episodic ataxia
  1670. Central vestibular dysfunction
  1671. Treatment of chronic peripheral vertigo
  1672. Vestibular rehabilitation physiotherapy
  1673. Particle repositioning procedures
  1674. Psychological treatment
  1675. Surgical management of vertigo
  1676. Hearing disorders
  1677. Anatomy and physiology
  1678. Definitions and introduction
  1679. Basic concepts
  1680. Conductive hearing loss
  1681. Sensorineural hearing loss
  1682. Auditory neuropathy
  1683. Brainstem auditory dysfunction
  1684. Auditory processing disorder
  1685. Clinical examination of the ear and hearing
  1686. Otoscopy
  1687. Auricle (pinna)
  1688. External auditory meatus
  1689. Tympanic membrane and middle ear
  1690. Tuning fork tests
  1691. Audiological investigations
  1692. Baseline audiometric tests
  1693. Pure‐tone audiometry
  1694. Acoustic impedance measurements
  1695. Speech audiometry
  1696. Electro‐acoustic and electrophysiological tests
  1697. Oto‐acoustic emissions
  1698. Cochlear microphonics and electro‐cochleography
  1699. Acoustic brainstem evoked responses
  1700. Middle latency response
  1701. Cortical‐evoked auditory responses
  1702. Aetiology of hearing loss
  1703. Conductive hearing loss
  1704. Disorders of the tympanic membrane and middle ear
  1705. Sensorineural hearing loss
  1706. Genetic hearing loss
  1707. Metabolic disease
  1708. Drugs
  1709. Acoustic trauma
  1710. Autoimmune disorders (Table 15.12)
  1711. Retro‐cochlear hearing disorders
  1712. Charcot–Marie–Tooth disease
  1713. Neurofibromatosis type 2
  1714. Friedreich’s ataxia
  1715. Refsum’s disease
  1716. Mitochondrial disorders
  1717. Inherited muscle disorders
  1718. Acquired retro‐cochlear hearing disorders (Table 15.14)
  1719. Extrinsic and intrinsic tumours of the cerebellopontine angle
  1720. Multiple sclerosis
  1721. Sarcoidosis
  1722. Vascular disease
  1723. Superficial siderosis
  1724. Auditory processing disorders
  1725. Aetiology of APD
  1726. Cortical hearing impairment
  1727. Auditory agnosia
  1728. Interhemispheric lesions
  1729. Management of auditory disorders
  1730. Hearing aids
  1731. Conductive hearing loss
  1732. Sensorineural hearing loss
  1733. VIIIth nerve disorders
  1734. Amplification and rehabilitation strategies
  1735. Auditory processing disorders
  1736. Environmental modifications
  1737. Signal enhancement strategies
  1738. Relatives and carers: speaker‐based adaptations
  1739. Auditory training programmes and compensatory strategies
  1740. References
  1741. Further reading
  1742. 16: Spinal Column and Spinal Cord Disorders
  1743. Spinal embryology, anatomy and physiology
  1744. Embryology of the spine
  1745. Genetic control of spinal development
  1746. Identifying genetic mutations involved in spinal anomaly
  1747. Anatomy and physiology of spinal maldevelopment
  1748. Disorders of axonal guidance
  1749. Congenital mirror movements
  1750. Human vertebral segmentation defects
  1751. Diagnosis of spinal column and spinal cord disorders
  1752. Clinical assessment of spinal disorders
  1753. Craniocervical junction
  1754. Syringobulbia and syringomyelia
  1755. Cervical spine
  1756. Thoracic spine
  1757. Lumbar and sacrococcygeal spine
  1758. Other clinical features of spinal disease
  1759. Diagnosis of spinal tumours
  1760. Clinical features of vascular disorders of the spine
  1761. Diagnosis of spinal vascular disease
  1762. Radiological assessment of spinal disorders
  1763. Specific diseases of the spinal column and spinal cord and their management
  1764. Skeletal disorders affecting the spine
  1765. Idiopathic scoliosis
  1766. Congenital scoliosis
  1767. Neuromuscular scoliosis
  1768. Kyphosis and lordosis
  1769. Miscellaneous causes of spinal deformity
  1770. Management of spinal deformity
  1771. Surgical correction of spinal deformity
  1772. Cranio‐cervical junction anomalies
  1773. Down’s syndrome
  1774. Chiari malformations
  1775. Congenital basilar invagination
  1776. Os odontoideum
  1777. Management of craniocervical junction anomalies
  1778. Syringomyelia
  1779. Spinal dysraphsim
  1780. Klippel–Feil syndrome
  1781. Rheumatological disorders affecting the spine and spinal cord
  1782. Indications for surgical management of the rheumatoid spine
  1783. Spondyloarthropathies
  1784. Spinal trauma
  1785. Acute management of spinal injury
  1786. Spinal tumours
  1787. Degenerative disease of the spine
  1788. Low back pain and degenerative disc disease
  1789. Spinal infections
  1790. Spinal cord inflammation
  1791. Vascular disorders of the spine
  1792. Management of spinal vascular disease
  1793. Metabolic diseases of the spinal cord
  1794. Hereditary spastic paraplegia
  1795. Miscellaneous conditions affecting the spine and spinal cord
  1796. Further reading
  1797. Physiology
  1798. Spinal cord development and repair
  1799. Spinal cord trauma
  1800. Spinal tumours
  1801. Rheumatoid diseases
  1802. Infections
  1803. Other medical conditions affecting the spinal cord
  1804. Scoliosis
  1805. Other surgical
  1806. Degenerative spine disease
  1807. 17: Cerebellar Ataxias and Related Conditions
  1808. Approach to the patient with ataxia
  1809. Symptoms
  1810. Physical signs
  1811. Additional signs
  1812. The ataxic disorders
  1813. Inherited ataxia syndromes
  1814. Congenital ataxias
  1815. Autosomal recessive cerebellar ataxias
  1816. Friedreich’s ataxia
  1817. Ataxic disorders associated with defective DNA repair
  1818. Ataxias associated with oculomotor apraxia
  1819. Ataxia caused by vitamin E deficiency
  1820. Autosomal recessive spastic ataxia of Charlevoix‐Saguenay
  1821. Other metabolic causes of ataxia
  1822. Intermittent metabolic ataxias
  1823. Progressive metabolic ataxias
  1824. Autosomal dominant cerebellar ataxias
  1825. Dentato‐rubro‐pallido‐luysian atrophy
  1826. Investigations
  1827. Treatment
  1828. Genetic forms of episodic ataxia
  1829. Episodic ataxia type 1
  1830. Episodic ataxia type 2
  1831. Other episodic ataxias
  1832. X‐linked ataxia syndromes
  1833. Mitochondrial ataxia syndromes
  1834. Next generation gene sequencing
  1835. Acquired ataxia syndromes
  1836. Infective disease
  1837. Acute or subacute onset
  1838. Progressive ataxia with a chronic or subacute course
  1839. Inflammatory disease
  1840. Vascular disease
  1841. Vascular anomalies
  1842. Acquired metabolic disorders
  1843. Toxins and physical agents
  1844. Ethyl alcohol (ethanol)
  1845. Drugs
  1846. Solvents and solvent abuse
  1847. Heavy metals
  1848. Physical agents
  1849. Paraneoplastic cerebellar degeneration
  1850. Late onset cerebellar degenerations
  1851. Multiple system atrophy
  1852. Ataxia and sensitivity to gluten
  1853. Idiopathic late onset ataxia
  1854. Conclusions
  1855. References
  1856. Further reading
  1857. 18: Restorative Neurology, Rehabilitation and Brain Injury
  1858. The nature of disability and its optimal management
  1859. Key aspects of multi‐dimensional rehabilitation
  1860. Natural histories of neurological damage
  1861. Disease/Health condition (organ disorder/pathology) (ICD-10) Subjective quality of life and well-being
  1862. Impairments
  1863. Activities
  1864. Participation
  1865. Resources, integrated care pathways, effectiveness and evidence base
  1866. Neural reorganisation and restoration
  1867. Treatment of neurological impairments and functional limitations
  1868. Restorative and compensatory approaches, skill learning and task‐related training
  1869. Physical therapeutic interventions for motor disorders
  1870. Bobath approach and Motor Relearning Programme
  1871. Impairment based treatment techniques
  1872. Constraint induced movement therapy
  1873. Balance and posture
  1874. Treadmill training, functional electrical stimulation, cueing, fitness and mental imagery
  1875. Robotics and virtual reality
  1876. Language disorders: speech and language therapy and communication aids
  1877. Visual loss and restorative therapies
  1878. Cognitive impairments
  1879. Environmental manipulation and compensatory strategies
  1880. Restorative approaches
  1881. Executive function, retraining and behavioural modification
  1882. Telerehabilitation
  1883. Vocational rehabilitation
  1884. Medical treatments for specific problems
  1885. Spasticity
  1886. Ataxia
  1887. Pain
  1888. Bladder, bowel and sexual dysfunction
  1889. Fatigue
  1890. Dysphagia
  1891. Neuropsychiatric problems
  1892. Single incident brain injury
  1893. Stroke
  1894. Traumatic brain injury
  1895. Service delivery
  1896. Organisational behaviours and interdisciplinary assessment
  1897. Assessment
  1898. Goal‐setting
  1899. Outcome measurement
  1900. Indices of outcome
  1901. Service quality
  1902. Conclusions
  1903. Further reading
  1904. General texts
  1905. Epidemiology
  1906. Guidelines
  1907. Restorative neurology
  1908. Skill learning and task‐related training
  1909. Physical therapeutic interventions for motor disorders
  1910. Language disorders
  1911. Visual loss
  1912. Cognitive impairments
  1913. Telerehabilitation
  1914. Medical treatments
  1915. Single incident brain injury Stroke
  1916. Traumatic brain injury
  1917. Organisational behaviours
  1918. 19: Toxic, Metabolic and Physical Insults to the Nervous System and Inherited Disorders of Metabolism
  1919. Neurological disorders associated with exposure to toxic substances
  1920. Heavy metals
  1921. Lead
  1922. Mercury
  1923. Arsenic
  1924. Manganese
  1925. Aluminium
  1926. Thallium
  1927. Tin
  1928. Bismuth
  1929. Solvents and toxins
  1930. Toluene
  1931. Trichloroethylene and tetrachlorethylene
  1932. Ethylene oxide
  1933. Hexacarbon solvents
  1934. Xylene and styrene
  1935. Carbon disulfide
  1936. Cyanide
  1937. Acrylamide and acylonitrile
  1938. Allyl chloride
  1939. Methyl bromide
  1940. Methyl chloride
  1941. Methyl alcohol (Methanol)
  1942. Nitrous oxide
  1943. Organophosphates
  1944. Carbon monoxide
  1945. Marine toxins
  1946. Ingested toxins
  1947. Other biological toxins
  1948. Snake venom
  1949. Spider toxins
  1950. Scorpion toxin
  1951. Ticks
  1952. Fungal poisons
  1953. Lathyrism
  1954. Konzo
  1955. Subacute myelo‐optico neuropathy
  1956. Tropical myelo‐neuropathy
  1957. Radiation‐induced neurological disease
  1958. Therapeutic radiation
  1959. Early‐delayed radiation encephalopathy
  1960. Late‐delayed radiation encephalopathy
  1961. Transient radiotherapy myelopathy
  1962. Radiation plexopathy
  1963. Lightning and electrical damage to the nervous system
  1964. Mechanisms of lightning and other electrical damage
  1965. Lightning: initiation and pattern of contact
  1966. Electrical injuries: high and low‐voltage
  1967. Nervous system complications of lightning and electrical injury
  1968. Non‐nervous system complications of lightning and electrical injury
  1969. Cardiac
  1970. Skin and muscle damage
  1971. Management
  1972. Heat stroke
  1973. Hypothermia and non‐freezing cold injury
  1974. Diving
  1975. Decompression sickness
  1976. Arterial and venous gas emboli
  1977. Altitude medicine
  1978. Acute mountain sickness and cerebral oedema
  1979. High altitude pulmonary oedema
  1980. Neurobiological weapons
  1981. Modes of release
  1982. Nerve agents
  1983. Organophosphates
  1984. Other toxins and poisons
  1985. Vitamin deficiencies and toxicity
  1986. Vitamin A
  1987. Vitamin B
  1988. thiamine)
  1989. Vitamin B
  1990. niacin, nicotinic acid)
  1991. Vitamin B
  1992. pyridoxine)
  1993. Vitamin B
  1994. deficiency (see Chapter 16)
  1995. Subacute combined degeneration of the cord
  1996. Folate deficiency
  1997. Vitamin D
  1998. Vitamin E
  1999. Alcohol abuse
  2000. Metabolism of alcohol
  2001. Effects of acute intoxication
  2002. Effects of alcohol substitutes
  2003. Methyl alcohol (methanol)
  2004. Ethylene glycol
  2005. Withdrawal syndromes
  2006. Withdrawal seizures (‘rum fits’)
  2007. Management of alcohol withdrawal
  2008. Chronic disorders associated with prolonged alcohol abuse
  2009. Wernicke’s encephalopathy
  2010. Korsakoff’s syndrome
  2011. Cerebellar ataxia
  2012. Confusional state and dementia
  2013. Alcoholic peripheral neuropathy
  2014. Alcoholic myopathy
  2015. Other neurological complications of alcohol abuse
  2016. Marchiafava–Bignami syndrome
  2017. Fetal alcohol syndrome
  2018. Psychiatric sequelae
  2019. Traumatic injury
  2020. Compressive neuropathies (see Chapter 10)
  2021. Amblyopia (see Chapter 14)
  2022. Alcoholic cirrhosis
  2023. Strachan’s syndrome
  2024. Other deficiency states associated with neurological manifestations
  2025. Copper deficiency
  2026. Magnesium deficiency
  2027. Drugs of abuse
  2028. Epidemiology
  2029. Stimulants
  2030. Amphetamines
  2031. Designer drugs
  2032. Methylphenidate (Ritalin)
  2033. Methcathinone analogues – khat
  2034. MPTP
  2035. Cocaine
  2036. Conditions caused by stimulant abuse
  2037. Sedatives
  2038. Opiates
  2039. Barbiturates
  2040. Benzodiazepines
  2041. Hallucinogens
  2042. Lysergic acid diethylamide
  2043. Marijuana
  2044. Ketamine
  2045. Phencyclidine (angel dust)
  2046. GABA hydroxybutyrate
  2047. Anticholinergics
  2048. Solvents
  2049. Athletic performance‐enhancing drugs
  2050. Investigation of suspected substance abuse
  2051. Adverse reactions to drugs
  2052. Seizures
  2053. Headache
  2054. Confusional states
  2055. Encephalopathy
  2056. Memory disturbance
  2057. Neuropsychiatric effects
  2058. Coma
  2059. Sleep disorders
  2060. Toxic leukoencephalopthy
  2061. Cerebrovascular disease
  2062. Impairment of taste and small
  2063. Drug‐induced movement disorders (Chapter 6)
  2064. Ototoxicity
  2065. Cerebellar disorders
  2066. Visual disorders
  2067. Autonomic effects
  2068. Neuromuscular drug effects
  2069. Peripheral neuropathy
  2070. Drugs interfering with neuromuscular transmission
  2071. Myalgia, stiffness and cramp
  2072. Malignant hyperthermia
  2073. Neuroleptic malignant syndrome
  2074. Serotonin syndrome
  2075. Tyramine cheese reaction
  2076. Anticholinergic syndrome caused by medication toxicity
  2077. Inherited disorders of metabolism
  2078. Porphyria
  2079. Acute intermittent porphyria
  2080. Diagnosis
  2081. Management
  2082. Disorders of amino acid metabolism
  2083. Phenylketonuria
  2084. Organic acidemias
  2085. Maple syrup urine disease
  2086. Isovaleric acidemia
  2087. Propionic acidemia and methylmalonic acidemia
  2088. Disorders of homocysteine metabolism
  2089. Transsulfuration defects
  2090. Remethylation Trans-sulfuration
  2091. Defects in intracellular cobalamin metabolism
  2092. Urea cycle disorders
  2093. Diagnosis
  2094. Management
  2095. Arginase deficiency
  2096. Disorders of carbohydrate metabolism
  2097. Glycogen storage diseases (the GSDs)
  2098. Hepatic involvement in glycogen storage diseases
  2099. Skeletal/cardiac muscle involvement in glycogen storage diseases
  2100. Central nervous system involvement in glycogen storage diseases
  2101. Galactosaemia
  2102. Fatty acid oxidation defects
  2103. Diagnosis
  2104. Management
  2105. Neurotransmitter disorders
  2106. Clinical presentations
  2107. Laboratory diagnosis
  2108. Management
  2109. Lysosomal storage disorders
  2110. Glycosphingolipidoses
  2111. Adult onset inherited leukodystrophies
  2112. X‐linked adrenoleukodystrophy
  2113. Krabbe disease
  2114. Cerebrotendinous xanthomatosis
  2115. Metachromatic leukodystrophy
  2116. Hereditary diffuse leukoencephalopathy with neuroaxonal spheroids
  2117. Alexander’s disease
  2118. Vanishing white matter disease
  2119. Pelizaeus–Merzbacher disease and Pelizaeus– Merzbacher‐like disease
  2120. Peroxisomal disorders
  2121. Refsum disease
  2122. Disorders of phospholipid and glycosphingolipid biosynthesis
  2123. Disorders of phospholipid synthesis
  2124. Disorders of glycosphingolipid synthesis
  2125. Acute neurological emergencies caused by inherited metabolic disease
  2126. References
  2127. Further reading
  2128. Toxins
  2129. Metabolic disorders
  2130. Physical insults
  2131. Drugs of abuse
  2132. Inborn errors of metabolism
  2133. 20: Disorders of Consciousness, Intensive Care Neurology and Sleep
  2134. Consciousness
  2135. States of impaired consciousness
  2136. Causes of coma
  2137. Initial assessment and management of coma
  2138. Medical assessment
  2139. Examination
  2140. Level of consciousness
  2141. Glasgow Coma Scale
  2142. Assessment of neurological function
  2143. Distinction of metabolic and toxic coma from structural coma
  2144. Psychogenic unresponsiveness
  2145. Outcome from coma
  2146. Aetiology
  2147. Depth of coma
  2148. Duration of coma
  2149. Presence of seizures
  2150. Co‐morbidity
  2151. Investigations
  2152. Locked‐in syndrome
  2153. Vegetative state
  2154. Minimally conscious state
  2155. Determining brain death
  2156. Repetition of testing
  2157. Neurological intensive care
  2158. Indications for intensive care management of neurological patients
  2159. Ventilatory failure associated with neurological disease
  2160. Neurological indications for tracheal intubation and mechanical ventilation
  2161. Mechanical ventilation
  2162. Weaning
  2163. Conditions requiring neurointensive care support
  2164. Raised intracranial pressure
  2165. Measurement of intracranial pressure
  2166. Indications for intracranial pressure monitoring
  2167. Management
  2168. Cerebral herniation
  2169. Herniation of the temporal lobe through the tentorium (uncal herniation)
  2170. Central herniation of the brainstem
  2171. Subfalcine herniation
  2172. Upward transtentorial herniation
  2173. Tonsillar herniation
  2174. Traumatic brain injury
  2175. Skull fractures
  2176. Extradural haematoma
  2177. Subdural haematoma
  2178. Traumatic subarachnoid haemorrhage
  2179. Haemorrhagic contusions and lacerations
  2180. Intracerebral haematoma
  2181. Diffuse axonal injury
  2182. Cerebral ischaemia
  2183. Intensive care management of TBI
  2184. Hydrocephalus and shunts
  2185. Investigations
  2186. Management
  2187. Stroke (Chapter 5)
  2188. Middle cerebral artery occlusion
  2189. Acute basilar occlusion
  2190. Artery of Percheron
  2191. Cerebellar infarcts
  2192. Subarachnoid haemorrhage
  2193. Supratentorial intracerebral haemorrhage (basal ganglia or lobar)
  2194. Infratentorial intracranial haemorrhage (cerebellar or brainstem)
  2195. Cerebral venous thrombosis
  2196. Seizures (Chapter 7)
  2197. Status epilepticus (SE)
  2198. Acute bacterial meningitis
  2199. Herpes simplex encephalitis
  2200. Autoimmune encephalopathy
  2201. Limbic encephalitis associated with neuronal surface antigens
  2202. Morvan’s syndrome
  2203. Encephalitis due to NMDA receptor antibodies
  2204. Steroid responsive encephalopathy
  2205. Other antibody‐mediated encephalomyelopathies
  2206. Metabolic encephalopathy
  2207. Septic encephalopathy
  2208. Uraemic encephalopathy
  2209. Hepatic encephalopathy
  2210. Hyperpyrexia and hyperthermia
  2211. Hypernatraemia
  2212. Hyponatraemia
  2213. Cerebral salt wasting
  2214. Central pontine myelinolysis
  2215. Posterior reversible encephalopathy syndrome
  2216. Hypoxic–ischaemic brain injury
  2217. Prognostic factors following cardiac arrest
  2218. Seizures
  2219. Longer‐term complications of HIBI
  2220. Movement disorder emergencies
  2221. Stiff person syndromes and progressive encephalopathy with rigidity and myoclonus
  2222. Acute dystonia
  2223. Stridor
  2224. Cervical cord disorders (Chapter 16)
  2225. Anterior horn cell disease
  2226. Neuromuscular disease
  2227. Neuropathies (Chapter 10)
  2228. Neuromuscular junction disease
  2229. Muscle disease
  2230. Tetanus (Chapter 9)
  2231. Rabies (Chapter 9)
  2232. General medical care on the NICU
  2233. Nosocomial infection and infection surveillance
  2234. Anticoagulation
  2235. Delirium
  2236. Patient comfort
  2237. Pain
  2238. Communication
  2239. Sleep
  2240. Communication with the family
  2241. End of life issues on intensive care
  2242. Neurology of general critical care
  2243. Failure to awaken/depressed conscious state
  2244. Weakness and failure to wean from mechanical ventilation
  2245. Sleep and its disorders
  2246. Structure of normal sleep
  2247. REM sleep
  2248. Patterns of sleep
  2249. Regulation of wakefulness and sleep
  2250. Functions of sleep
  2251. Sleep and breathing
  2252. Classification of sleep disorders
  2253. Insomnia
  2254. Management
  2255. Sleep‐related breathing disorders
  2256. Obstructive sleep apnoea/hypopnoea syndrome
  2257. Hypersomnias of central origin
  2258. Primary (idiopathic) hypersomnia
  2259. Recurrent hypersomnia
  2260. Idiopathic recurring stupor
  2261. Excessive daytime somnolence in neurological disease
  2262. Narcolepsy
  2263. Cataplexy
  2264. Hypnogogic/hypnopompic hallucinations
  2265. Sleep paralysis and automatic behaviours
  2266. Pathophysiology of narcolepsy
  2267. Investigations
  2268. Management of narcolepsy
  2269. Circadian rhythm disorders
  2270. Delayed or advanced sleep phase syndrome
  2271. Shift work and jet lag
  2272. Parasomnias
  2273. Non‐REM parasomnias
  2274. REM sleep disorders
  2275. Other forms of parasomnia
  2276. Sleep‐related movement disorders
  2277. Restless legs syndrome
  2278. Periodic limb movements of sleep
  2279. Rhythmic movement disorders
  2280. Isolated symptoms, apparently normal variants
  2281. Other sleep disturbances in extrapyramidal disease
  2282. Epilepsy syndromes associated with sleep
  2283. Traumatic brain injury and sleep
  2284. Acknowledgement
  2285. References
  2286. Further reading
  2287. States of impaired consciousness
  2288. Brain death
  2289. Neurological intensive care
  2290. Encephalopathy
  2291. Neuromuscular
  2292. Sleep
  2293. 21: Neuro‐Oncology
  2294. Epidemiology of common primary intracranial tumours
  2295. Incidence
  2296. Survival
  2297. Risk factors
  2298. Clinical features
  2299. Headache
  2300. Seizures
  2301. Focal deficits
  2302. Brainstem symptoms
  2303. Cognitive and behavioural symptoms
  2304. Endocrine symptoms
  2305. Rare presentations
  2306. Histogenesis of brain cancer
  2307. Molecular mechanisms involved in tumour formation
  2308. Genetic components in oncogenesis
  2309. Epigenetic events in oncogenesis
  2310. WHO classification of CNS tumours
  2311. Neuroepithelial tumours
  2312. Imaging of brain tumours
  2313. Structural imaging
  2314. Physiological imaging
  2315. Diffusion‐weighted imaging
  2316. Perfusion‐weighted imaging
  2317. Permeability imaging (Ktrans)
  2318. MR spectroscopy
  2319. Functional MRI
  2320. Applications of physiological imaging
  2321. Distinguishing between astrocytomas and oligodendrogliomas
  2322. Distinguishing between low‐grade and high‐grade gliomas
  2323. Imaging of peri‐tumoural tissue
  2324. Monitoring tumour growth and response to treatment
  2325. Pseudoprogression and pseudoresponse
  2326. Imaging the effects of radiotherapy
  2327. Radiation‐induced leukoencephalopathy
  2328. Radiation necrosis
  2329. Optic neuropathy
  2330. Radiation‐induced tumours
  2331. Imaging complications of chemotherapy
  2332. Multidisciplinary management of brain tumours
  2333. Improving outcome and quality of life
  2334. Surgical management
  2335. General principles
  2336. Surgical instrumentation and methods
  2337. Radiotherapy
  2338. Radiotherapy planning
  2339. Radiation neurotoxicity
  2340. High‐grade gliomas
  2341. Pathology
  2342. Anaplastic astrocytoma
  2343. Glioblastoma
  2344. Imaging
  2345. Anaplastic astrocytoma
  2346. Glioblastoma
  2347. Surgery
  2348. Radiotherapy
  2349. Chemoradiation
  2350. Chemotherapy
  2351. Relapsed high‐grade gliomas
  2352. Anaplastic oligodendrogliomas
  2353. Low‐grade gliomas
  2354. Pathology
  2355. Pilocytic astrocytoma
  2356. Diffuse astrocytoma
  2357. Oligodendroglioma
  2358. Oligoastrocytoma
  2359. Imaging
  2360. Pilocytic astrocytoma
  2361. Diffuse astrocytoma
  2362. Oligodendroglioma
  2363. Surgery for low‐grade gliomas
  2364. Pilocytic astrocytoma
  2365. Diffuse astrocytoma and oligodendroglioma
  2366. Radiotherapy for low‐grade gliomas
  2367. Chemotherapy for low‐grade gliomas
  2368. Other low‐grade tumours in childhood
  2369. Tumours of predominantly neuronal cell origin
  2370. Gangioglioma and gangliocytoma
  2371. Central neurocytoma
  2372. Dysembryoplastic neuroepithelial tumour
  2373. Choroid plexus tumours
  2374. Meningiomas
  2375. Pathology
  2376. Imaging
  2377. Surgery
  2378. Radiotherapy
  2379. Chemotherapy
  2380. Brain metastases
  2381. Pathology
  2382. Imaging
  2383. Surgery and/or radiotherapy
  2384. Chemotherapy
  2385. Primary spinal cord tumours
  2386. Surgery
  2387. Chemotherapy for intrinsic cord tumours
  2388. Spinal ependymomas
  2389. Spinal astrocytomas
  2390. Spinal meningiomas and schwannomas
  2391. Metastatic spinal cord compression
  2392. Skull base tumours
  2393. Chordoma
  2394. Pathology
  2395. Imaging
  2396. Treatment
  2397. Chondrosarcoma
  2398. Neurofibromatosis and schwannomas
  2399. Pathology
  2400. Molecular genetics
  2401. Clinical features
  2402. Skull base meningiomas
  2403. Pituitary tumours
  2404. Biological behaviour
  2405. Size
  2406. Histology
  2407. Functional criteria
  2408. Clinical presentation
  2409. Pituitary apoplexy
  2410. Drug therapy and surgery
  2411. Radiotherapy
  2412. Craniopharyngioma
  2413. Primary CNS lymphomas
  2414. Imaging
  2415. Pathology
  2416. Clinical presentation
  2417. Diagnosis
  2418. Treatment
  2419. Primitive neuroepithelial tumours and medulloblastomas
  2420. Pathology
  2421. Molecular genetics and histogenesis of medulloblastoma
  2422. Imaging
  2423. Clinical features
  2424. Treatment
  2425. Pineal region tumours
  2426. Introduction
  2427. Pathology
  2428. Clinical features
  2429. Treatment
  2430. Germ cell tumours
  2431. Optic pathway glioma
  2432. Treatment of optic pathway glioma
  2433. Ependymomas
  2434. Pathology
  2435. Imaging
  2436. Treatment
  2437. Dermoids and epidermoid cysts
  2438. Imaging
  2439. Haemangioblastomas
  2440. Colloid cysts, Rathke’s pouch tumours and neuro‐enteric cysts
  2441. Neurological complications of cancer
  2442. Direct effects and infiltration
  2443. Metastases
  2444. Malignant meningitis
  2445. Clinical features
  2446. Diagnosis
  2447. Treatment
  2448. Indirect effects of cancer
  2449. Toxic and metabolic encephalopathy
  2450. Vascular disorders
  2451. Non‐bacterial thrombotic endocarditis
  2452. CNS infections in cancer patients
  2453. Paraneoplastic neurological disorders
  2454. Incidence and prevalence
  2455. Clinical features
  2456. Paraneoplastic cerebellar degeneration
  2457. Paraneoplastic encephalomyelitis and limbic encephalitis
  2458. Brainstem encephalitis
  2459. Paraneoplastic encephalomyelitis with rigidity
  2460. Paraneoplastic opsoclonus‐myoclonus
  2461. Paraneoplastic retinal degeneration
  2462. Necrotising myelopathy
  2463. Motor neurone syndromes
  2464. Paraneoplastic sensory neuronopathy
  2465. Paraneoplastic neuropathies
  2466. Neuromyotonia
  2467. Lambert–Eaton myasthenic syndrome
  2468. Myasthenia gravis
  2469. Polymyositis and dermatomyositis
  2470. Acute necrotising myopathy
  2471. Diagnosis of PND
  2472. Paraneoplastic antineuronal autoantibodies
  2473. Imaging
  2474. Treatment for PND
  2475. Neurological complications of chemotherapy
  2476. Polyneuropathy
  2477. Encephalopathy
  2478. Further reading
  2479. Epidemiology
  2480. Clinical features
  2481. Pathology
  2482. Imaging
  2483. Surgery, radiotherapy and chemotherapy
  2484. Quality of life
  2485. Paraneoplastic neurological syndromes
  2486. Malignant meningitis
  2487. Brain tumour charities and support services
  2488. 22: Neuropsychiatry
  2489. The mental state examination
  2490. Appearance and behaviour
  2491. Speech
  2492. Mood and affect
  2493. Thoughts
  2494. Formal thought disorder
  2495. Thought content
  2496. Perceptions
  2497. Cognition
  2498. Insight
  2499. Formulation
  2500. Identifying and managing risk secondary to abnormal mental states
  2501. Agitation and aggression
  2502. Lack of insight
  2503. Suicidal ideation/suicidal behaviour
  2504. Legal issues: use of mental health and capacity acts
  2505. Psychiatric symptoms commonly seen in neurological disorders
  2506. Personality change
  2507. Obsessions and compulsions
  2508. Anxiety
  2509. Mood
  2510. Pseudodementia
  2511. Psychosis
  2512. Catatonia
  2513. Non‐organic disorders in neurology
  2514. Functional neurological symptoms
  2515. Terminology
  2516. Diagnosis
  2517. Specific types of functional neurological symptoms
  2518. Functional seizures
  2519. Fixed dystonia
  2520. Treatment of functional neurological symptoms
  2521. Dissociative disorders
  2522. Dissociative amnesia
  2523. Dissociative fugue
  2524. Depersonalisation/derealisation disorder
  2525. Psychiatric disorders of epilepsy
  2526. Peri‐ictal and ictal psychiatric symptoms
  2527. Inter‐ictal psychiatric disorders
  2528. Forced normalisation
  2529. Personality changes in epilepsy
  2530. Psychotropic effects of anticonvulsants
  2531. Neuropsychiatric aspects of movement disorders
  2532. Parkinson’s disease
  2533. Depression
  2534. Anxiety
  2535. Apathy
  2536. Psychosis
  2537. Cognitive impairment
  2538. Iatrogenic neuropsychiatric problems
  2539. Other movement disorders
  2540. Neuropsychiatric aspects of white matter disorders
  2541. Minor head injury and post‐concussion syndrome
  2542. Acknowledgement
  2543. Further reading
  2544. General
  2545. Functional neurological symptoms
  2546. Epilepsy
  2547. Movement disorders
  2548. 23: Pain
  2549. Definitions
  2550. Mechanisms of neuropathic pain
  2551. Peripheral neuropathy
  2552. Abnormal ion channel expression
  2553. Spinal cord
  2554. Central sensitisation and ‘wind‐up’
  2555. Excitatory mechanisms
  2556. Inhibitory mechanisms
  2557. Role of inflammation and the immune system
  2558. Supraspinal influences
  2559. Assessment of pain in the patient with neurological disease
  2560. The pain history
  2561. Treatment history
  2562. Physical examination
  2563. Central spinal pain: some anatomical and pathological considerations
  2564. Pain in individual disorders of the central nervous system
  2565. Multiple sclerosis
  2566. Neuropathic paroxysmal pain
  2567. Neuropathic non‐paroxysmal pain
  2568. Nociceptive pain
  2569. Parkinson’s disease
  2570. Neuropathic (central) pain
  2571. Dystonia/dyskinesia pain
  2572. Central post‐stroke pain
  2573. Spinal cord injury
  2574. Syringomyelia
  2575. Phantom pain
  2576. Painful legs and moving toes syndrome
  2577. Epilepsy
  2578. Fibromyalgia
  2579. Peripheral pain: anatomical and pathological considerations (Chapter 2)
  2580. Pain in individual disorders of the peripheral nervous system
  2581. Painful peripheral neuropathies
  2582. Burning feet, and the small‐diameter fibre neuropathies
  2583. Erythromelalgia
  2584. Treatment
  2585. Neuropathy in diabetes mellitus (Chapter 10)
  2586. Shingles and post‐herpetic neuralgia: shingles
  2587. Post‐herpetic neuralgia
  2588. Guillain–Barré syndrome
  2589. Neuralgic amyotrophy (brachial neuritis)
  2590. Painful inherited neuropathies
  2591. Latrogenic painful peripheral nerve lesions
  2592. Complex regional pain syndrome
  2593. Pain associated with benign orthopaedic conditions
  2594. Glomus tumour
  2595. Osteoid osteoma
  2596. Motor neurone disease
  2597. Painful peripheral viscero‐somatic disorders
  2598. Burning mouth syndrome
  2599. Vulvodynia
  2600. Visceral pain
  2601. Plexopathies
  2602. Traumatic brachial plexus lesions
  2603. Malignant and radiation‐induced plexopathies
  2604. Management
  2605. Management of neuropathic pain
  2606. Systemic drug treatments
  2607. Opioids and other analgesics
  2608. Antidepressants
  2609. Antiepileptics
  2610. Local anaesthetics and related compounds
  2611. NMDA receptor antagonists
  2612. Cannabinoids
  2613. Topical agents
  2614. Botulinum toxin
  2615. Intrathecal drugs
  2616. Neuro‐ablative and neuro‐stimulation procedures
  2617. Neuro‐ablative procedures
  2618. Neuro‐stimulation procedures
  2619. Other physical methods of treatment
  2620. Acupuncture
  2621. Psychological approaches to management of chronic pain
  2622. The placebo phenomenon
  2623. Insensitivity to pain
  2624. Congenital insensitivity to pain
  2625. Transient indifference to pain
  2626. Conclusions
  2627. Acknowledgement
  2628. References
  2629. Further reading
  2630. General
  2631. Classic papers on pain
  2632. Clinical assessment
  2633. Specific Conditions
  2634. Treatment and the placebo response
  2635. 24: Autonomic Aspects of Neurology
  2636. Classification of autonomic dysfunction
  2637. Clinical features
  2638. Cardiovascular system
  2639. Orthostatic hypotension
  2640. Syncope without orthostatic hypotension
  2641. Orthostatic intolerance with posturally induced tachycardia
  2642. Hypertension
  2643. Heart rate disturbances
  2644. Facial and peripheral vascular changes
  2645. Sudomotor system
  2646. Alimentary system
  2647. Kidneys and urinary tract
  2648. Sexual function
  2649. Eyes and lacrimal glands
  2650. Respiratory system
  2651. Additional features of neurological conditions: MSA and Parkinson’s disease
  2652. Psychological and psychiatric disturbances
  2653. Clinical examination
  2654. Investigations
  2655. Management
  2656. Cardiovascular system
  2657. Orthostatic hypotension
  2658. Supine hypertension
  2659. Autonomic mediated syncope
  2660. Postural tachycardia syndrome
  2661. Hypertension
  2662. Sudomotor disorders
  2663. Anhidrosis
  2664. Hyperhidrosis
  2665. Alimentary system
  2666. Urinary tract
  2667. Sexual function and the reproductive system
  2668. Respiratory system
  2669. Eye and lacrimal glands
  2670. Treatment in MSA and Parkinson’s disease
  2671. References
  2672. Further reading
  2673. 25: Uroneurology
  2674. The lower urinary tract and its neurological control
  2675. Lower urinary tract dysfunction following neurological disease
  2676. Cortical disease
  2677. Cerebrovascular disease
  2678. Dementia
  2679. Parkinson’s disease
  2680. Multiple system atrophy
  2681. Brainstem lesions
  2682. Spinal cord disease
  2683. Multiple sclerosis
  2684. Other (non‐traumatic) spinal cord diseases
  2685. Sacral and infrasacral lesions
  2686. Conus or cauda equina lesions
  2687. Diabetic neuropathy
  2688. Other neuropathies
  2689. Pelvic nerve injury
  2690. Myotonic dystrophy
  2691. Urinary retention
  2692. Urinary retention in women
  2693. Management of lower urinary tract dysfunction
  2694. Management of storage dysfunction
  2695. Antimuscarinics (anticholinergics)
  2696. Desmopressin
  2697. Botulinum toxin
  2698. Neuromodulation
  2699. Management of voiding dysfunction
  2700. Sexual functions and its neurological control
  2701. Physiology
  2702. Sexual dysfunction following neurological disease
  2703. Traumatic brain injury
  2704. Stroke
  2705. Epilepsy
  2706. Parkinson’s disease
  2707. Multiple system atrophy
  2708. Spinal cord injury
  2709. Multiple sclerosis
  2710. Lesions of the sympathetic thoraco‐lumbar outflow
  2711. Conus or cauda equina lesions
  2712. Peripheral neuropathies
  2713. Management of sexual dysfunction
  2714. References
  2715. Further reading
  2716. 26: Systemic Conditions and Neurology
  2717. Aortic and cardiac disorders
  2718. Aortic pathology
  2719. Anatomy
  2720. Blood supply
  2721. Cerebral ischaemia resulting from aortic disease
  2722. Spinal cord ischaemia resulting from aortic disease
  2723. Neurological complications of cardiac surgery
  2724. Neurological complications of acquired cardiac disease
  2725. Cardiac embolism
  2726. Rhythm disturbances
  2727. Cardiomyopathies
  2728. Valve disease
  2729. Atrial myxoma
  2730. Endocrine conditions
  2731. Thyroid disorders
  2732. Hyperthyroidism
  2733. Hypothyroidism
  2734. Neurological aspects of Hashimoto’s thyroiditis
  2735. Diabetes mellitus
  2736. Acute metabolic disturbances
  2737. Diabetic neuropathies
  2738. Pituitary disorders
  2739. Inappropriate antidiuretic hormone secretion and cerebral salt wasting
  2740. Parathyroid disorderss
  2741. Adrenal disorders
  2742. Electrolyte disturbances
  2743. Sodium
  2744. Potassium
  2745. Calcium and magnesium
  2746. Haematological disorders
  2747. Anaemias
  2748. Proliferative conditions
  2749. Leukaemias
  2750. Plasma cell dyscrasias
  2751. Lymphomas
  2752. Langerhans cell histiocytosis
  2753. Polycythaemia
  2754. Thrombocythaemia
  2755. Bleeding disorders
  2756. Thrombotic thrombocytopenic purpura
  2757. Coagulation disorders
  2758. Primary immunodeficiency
  2759. Gastrointestinal disorders
  2760. Hepatic encephalopathy
  2761. Vitamin deficiencies causing neurological disorders
  2762. Vitamin B
  2763. deficiency
  2764. Vitamine B
  2765. niacin) deficiency (Pellagra)
  2766. Vitamin D deficiency
  2767. Vitamin E deficiency
  2768. Malabsorption
  2769. Coeliac disease
  2770. Inflammatory bowel disease
  2771. Renal disease
  2772. Conditions affecting both renal and neurological function
  2773. Neurological consequences of renal disease and its treatment
  2774. Uraemic encephalopathy
  2775. Dialysis encephalopathy
  2776. Dialysis disequilibrium syndrome
  2777. Neuropathy associated with renal disease
  2778. Neurological aspects of organ transplantation
  2779. CNS infections
  2780. Viral infection
  2781. Bacterial infection
  2782. Fungal infection
  2783. Parasitic infection
  2784. Neurological sequelae of transplantation
  2785. Seizures
  2786. Encephalopathy
  2787. Stroke
  2788. Medication
  2789. CNS malignancy
  2790. Neuro‐ophthalmological problems
  2791. Movement disorders
  2792. Neuromuscular problems
  2793. Complications related to specific allograft transplantation
  2794. Renal transplantation
  2795. Liver transplantation
  2796. Cardiac transplantation
  2797. Lung transplantation
  2798. Bone marrow transplantation
  2799. Neurological involvement in systemic vasculitides and related disorders
  2800. Pathological mechanisms
  2801. Diagnosis and treatment of vasculitides involving the nervous system
  2802. Polyarteritis nodosa and related conditions
  2803. Granulomatosis with polyangiitis (Wegener’s granulomatosis)
  2804. Giant cell arteritis
  2805. Isolated cerebral angiitis
  2806. Rheumatoid arthritis
  2807. Systemic lupus erythematosus
  2808. Antiphospholipid syndrome
  2809. Sjögren’s syndrome
  2810. Miscellaneous cerebral arteriopathies
  2811. CADASIL
  2812. CARASIL
  2813. Fabry’s disease
  2814. Susac’s syndrome
  2815. Sneddon’s syndrome
  2816. Degos’ disease
  2817. HANAC
  2818. Reversible cerebral vasoconstriction syndrome
  2819. Sarcoidosis
  2820. Clinical features and investigation
  2821. Cranial neuropathy
  2822. Meningeal and parenchymatous sarcoid
  2823. Sarcoid encephalopathy
  2824. Peripheral neuromuscular sarcoid
  2825. Diagnosis
  2826. Prognosis
  2827. Behçet’s syndrome
  2828. Epidemiology and pathology
  2829. Patterns of nervous system involvement
  2830. CNS involvement: parenchymal
  2831. Cerebral venous sinus thrombosis
  2832. Investigation
  2833. Pathergy test in Behçet’s disease
  2834. Treatment
  2835. IgG4‐related disease
  2836. CLIPPERS
  2837. Neurocutaneous syndromes
  2838. Neurofibromatosis type 1 (von Recklinghausen’s disease)
  2839. Neurofibromatosis type 2
  2840. Xeroderma pigmentosa
  2841. Tuberous sclerosis
  2842. Von Hippel–Lindau disease
  2843. Ataxia telangiectasia
  2844. Sturge–Weber syndrome
  2845. Neurological aspects of pregnancy
  2846. Epilepsy and women of childbearing age
  2847. Fertility
  2848. Pregnancy
  2849. Epilepsy and the fetus
  2850. Teratogenicity of antiepileptic drugs
  2851. Puerperium
  2852. Reducing risks of pregnancy to mother and child
  2853. Cerebrovascular disorders in pregnancy
  2854. Pregnancy and other neurological diseases
  2855. Pituitary disorders
  2856. Headache
  2857. Neuromuscular disorders
  2858. Multiple sclerosis
  2859. Chorea gravidarum
  2860. Tumours
  2861. Idiopathic intracranial hypertension
  2862. Complications of obstetric anaesthesia
  2863. Postpartum compression neuropathies
  2864. Other conditions causing acute neurological symptoms during pregnancy
  2865. Palliative and end of life care in neurology
  2866. The dying patient
  2867. References
  2868. Further reading
  2869. Cardiovascular disorders
  2870. Endocrine disorders
  2871. Haematological disorders
  2872. Gastro‐intestinal disorders
  2873. Renal disease
  2874. Vasculitis
  2875. Neurosarcoidosis, Sjögren
  2876. Behçet’s syndrome
  2877. Neurocutaneous disorders
  2878. Pregnancy
  2879. Palliative care
  2880. Index
Advertisement
Add Comment
Please, Sign In to add comment
Advertisement